ZA200504672B - Diazepanes derivatives useful as LFA inhibitors - Google Patents
Diazepanes derivatives useful as LFA inhibitors Download PDFInfo
- Publication number
- ZA200504672B ZA200504672B ZA200504672A ZA200504672A ZA200504672B ZA 200504672 B ZA200504672 B ZA 200504672B ZA 200504672 A ZA200504672 A ZA 200504672A ZA 200504672 A ZA200504672 A ZA 200504672A ZA 200504672 B ZA200504672 B ZA 200504672B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- methyl
- naphthalen
- oxo
- diazepan
- Prior art date
Links
- 150000000117 diazepanes Chemical class 0.000 title description 4
- 239000003112 inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 150
- 229940080818 propionamide Drugs 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 22
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- -1 substituted Chemical class 0.000 claims description 17
- 125000001475 halogen functional group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229960005222 phenazone Drugs 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 claims description 4
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims description 4
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims description 4
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 claims description 4
- 108010040082 Junctional Adhesion Molecule A Proteins 0.000 claims description 4
- 102100022304 Junctional adhesion molecule A Human genes 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical group CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 101100341510 Mus musculus Itgal gene Proteins 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims 3
- MAXIUBVBEVDVHA-UHFFFAOYSA-N 2-[3-(2-fluorophenyl)-5-methyl-2-oxo-4-(2-quinolin-6-ylacetyl)-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound C=1C=C2N=CC=CC2=CC=1CC(=O)N1C(C)CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C1C1=CC=CC=C1F MAXIUBVBEVDVHA-UHFFFAOYSA-N 0.000 claims 1
- MEBRQBUKOBSPKQ-UHFFFAOYSA-N 2-[3-(3,4-difluorophenyl)-5-methyl-2-oxo-4-(2-quinolin-6-ylacetyl)-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound C=1C=C2N=CC=CC2=CC=1CC(=O)N1C(C)CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C1C1=CC=C(F)C(F)=C1 MEBRQBUKOBSPKQ-UHFFFAOYSA-N 0.000 claims 1
- HMTFIZHCMHCDLS-UHFFFAOYSA-N 2-[3-(3-chlorophenyl)-4-[2-(2-methoxyphenyl)acetyl]-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound COC1=CC=CC=C1CC(=O)N1C(C=2C=C(Cl)C=CC=2)C(=O)N(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)CCC1C HMTFIZHCMHCDLS-UHFFFAOYSA-N 0.000 claims 1
- SSJHHSIDJFZRNI-UHFFFAOYSA-N 2-[3-(3-chlorophenyl)-5-methyl-2-oxo-4-[2-[4-(prop-2-enoylamino)phenyl]acetyl]-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(Cl)C=CC=2)N1C(=O)CC1=CC=C(NC(=O)C=C)C=C1 SSJHHSIDJFZRNI-UHFFFAOYSA-N 0.000 claims 1
- QUAJFBCLXWNUSN-UHFFFAOYSA-N 2-[3-(3-fluorophenyl)-5-methyl-2-oxo-4-[2-[3-(trifluoromethyl)phenyl]acetyl]-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(F)C=CC=2)N1C(=O)CC1=CC=CC(C(F)(F)F)=C1 QUAJFBCLXWNUSN-UHFFFAOYSA-N 0.000 claims 1
- HBZXEWDLYTUVIL-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-5-methyl-2-oxo-4-(2-quinolin-6-ylacetyl)-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound C=1C=C2N=CC=CC2=CC=1CC(=O)N1C(C)CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C1C1=CC=C(F)C=C1 HBZXEWDLYTUVIL-UHFFFAOYSA-N 0.000 claims 1
- BMGIRIXNNSFLHC-UHFFFAOYSA-N 2-[4-[2-(1,3-benzodioxol-5-yl)acetyl]-5-methyl-2-oxo-3-[3-(trifluoromethoxy)phenyl]-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound C=1C=C2OCOC2=CC=1CC(=O)N1C(C)CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C1C1=CC=CC(OC(F)(F)F)=C1 BMGIRIXNNSFLHC-UHFFFAOYSA-N 0.000 claims 1
- DFXRSCXCRGRQEX-UHFFFAOYSA-N 2-[4-[2-(4-aminophenyl)acetyl]-3-(3-chlorophenyl)-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(Cl)C=CC=2)N1C(=O)CC1=CC=C(N)C=C1 DFXRSCXCRGRQEX-UHFFFAOYSA-N 0.000 claims 1
- ZKRFHJROTFJRRN-UHFFFAOYSA-N 2-[4-[2-[3-[(2-aminoacetyl)amino]phenyl]acetyl]-3-(3-chlorophenyl)-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(Cl)C=CC=2)N1C(=O)CC1=CC=CC(NC(=O)CN)=C1 ZKRFHJROTFJRRN-UHFFFAOYSA-N 0.000 claims 1
- RHRFHBFPVQDTIU-UHFFFAOYSA-N 2-[4-[2-[4-(3-aminopropanoylamino)phenyl]acetyl]-3-(3-chlorophenyl)-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(Cl)C=CC=2)N1C(=O)CC1=CC=C(NC(=O)CCN)C=C1 RHRFHBFPVQDTIU-UHFFFAOYSA-N 0.000 claims 1
- KNHNSLKSKBTKPC-UHFFFAOYSA-N 2-[4-[2-[4-(dimethylamino)phenyl]acetyl]-5-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(C=CC=2)C(F)(F)F)N1C(=O)CC1=CC=C(N(C)C)C=C1 KNHNSLKSKBTKPC-UHFFFAOYSA-N 0.000 claims 1
- UFAMJQAMKUVMFF-UHFFFAOYSA-N 2-[4-[2-[4-[(2-aminoacetyl)amino]phenyl]acetyl]-3-(3-chlorophenyl)-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(Cl)C=CC=2)N1C(=O)CC1=CC=C(NC(=O)CN)C=C1 UFAMJQAMKUVMFF-UHFFFAOYSA-N 0.000 claims 1
- JOPRRGLLWAAKEM-UHFFFAOYSA-N 4-[3-[2-[4-(1-amino-3-naphthalen-1-yl-1-oxopropan-2-yl)-2-(3-chlorophenyl)-7-methyl-3-oxo-1,4-diazepan-1-yl]-2-oxoethyl]anilino]-4-oxobutanoic acid Chemical compound CC1CCN(C(CC=2C3=CC=CC=C3C=CC=2)C(N)=O)C(=O)C(C=2C=C(Cl)C=CC=2)N1C(=O)CC1=CC=CC(NC(=O)CCC(O)=O)=C1 JOPRRGLLWAAKEM-UHFFFAOYSA-N 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 34
- 238000000034 method Methods 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 21
- 102100025390 Integrin beta-2 Human genes 0.000 description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 206010012442 Dermatitis contact Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 208000002029 allergic contact dermatitis Diseases 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 4
- 108090000235 Myeloperoxidases Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 206010027654 Allergic conditions Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- PBLNHHSDYFYZNC-UHFFFAOYSA-N (1-naphthyl)methanol Chemical compound C1=CC=C2C(CO)=CC=CC2=C1 PBLNHHSDYFYZNC-UHFFFAOYSA-N 0.000 description 1
- HMTFIZHCMHCDLS-DEVXKSAMSA-N (2r)-2-[(3s,5r)-3-(3-chlorophenyl)-4-[2-(2-methoxyphenyl)acetyl]-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound COC1=CC=CC=C1CC(=O)N1[C@@H](C=2C=C(Cl)C=CC=2)C(=O)N([C@H](CC=2C3=CC=CC=C3C=CC=2)C(N)=O)CC[C@H]1C HMTFIZHCMHCDLS-DEVXKSAMSA-N 0.000 description 1
- MFXVFKCIJUQLOK-ZVDSLUNQSA-N (2r)-2-[(3s,5r)-3-(3-chlorophenyl)-4-[2-(4-cyanophenyl)acetyl]-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound N1([C@H](C(=O)N([C@H](CC=2C3=CC=CC=C3C=CC=2)C(N)=O)CC[C@H]1C)C=1C=C(Cl)C=CC=1)C(=O)CC1=CC=C(C#N)C=C1 MFXVFKCIJUQLOK-ZVDSLUNQSA-N 0.000 description 1
- JEZNYUZOGOIXDC-PBQZKXDYSA-N (2r)-2-[(3s,5r)-3-[4-chloro-3-(trifluoromethyl)phenyl]-5-methyl-2-oxo-4-(2-quinolin-6-ylacetyl)-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound C1([C@H]2C(=O)N([C@H](CC=3C4=CC=CC=C4C=CC=3)C(N)=O)CC[C@H](N2C(=O)CC=2C=C3C=CC=NC3=CC=2)C)=CC=C(Cl)C(C(F)(F)F)=C1 JEZNYUZOGOIXDC-PBQZKXDYSA-N 0.000 description 1
- DFXRSCXCRGRQEX-QLQSRUBLSA-N (2r)-2-[(3s,5r)-4-[2-(4-aminophenyl)acetyl]-3-(3-chlorophenyl)-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound N1([C@H](C(=O)N([C@H](CC=2C3=CC=CC=C3C=CC=2)C(N)=O)CC[C@H]1C)C=1C=C(Cl)C=CC=1)C(=O)CC1=CC=C(N)C=C1 DFXRSCXCRGRQEX-QLQSRUBLSA-N 0.000 description 1
- UITOSQHRNZPXKY-GYGCULMCSA-N (2r)-2-[(3s,5r)-4-[2-(4-cyanophenyl)acetyl]-3-(3,4-difluorophenyl)-5-methyl-2-oxo-1,4-diazepan-1-yl]-3-naphthalen-1-ylpropanamide Chemical compound N1([C@H](C(=O)N([C@H](CC=2C3=CC=CC=C3C=CC=2)C(N)=O)CC[C@H]1C)C=1C=C(F)C(F)=CC=1)C(=O)CC1=CC=C(C#N)C=C1 UITOSQHRNZPXKY-GYGCULMCSA-N 0.000 description 1
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 1
- KIAPYAZGXJCKQL-UHFFFAOYSA-N 2-[n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetic acid Chemical compound CC(C)(C)OC(=O)N(CC(O)=O)C1=CC=CC=C1 KIAPYAZGXJCKQL-UHFFFAOYSA-N 0.000 description 1
- VRAYTNFBRROPJU-UHFFFAOYSA-N 2-methoxy-1,3-dioxolane Chemical compound COC1OCCO1 VRAYTNFBRROPJU-UHFFFAOYSA-N 0.000 description 1
- JSKOSOPCDRFUQB-UHFFFAOYSA-N 2-naphthalen-1-ylpropanamide Chemical compound C1=CC=C2C(C(C(N)=O)C)=CC=CC2=C1 JSKOSOPCDRFUQB-UHFFFAOYSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
- RIUNOHRBTUNEAL-UHFFFAOYSA-N 3-o-tert-butyl 1-o-methyl 2-[amino(naphthalen-1-yl)methylidene]propanedioate Chemical compound C1=CC=C2C(C(N)=C(C(=O)OC(C)(C)C)C(=O)OC)=CC=CC2=C1 RIUNOHRBTUNEAL-UHFFFAOYSA-N 0.000 description 1
- PWBLNYLTLVRGNY-LCQPTLMKSA-N 4-[4-[2-[(2s,7r)-4-[(2r)-1-amino-3-naphthalen-1-yl-1-oxopropan-2-yl]-7-methyl-3-oxo-2-[3-(trifluoromethyl)phenyl]-1,4-diazepan-1-yl]-2-oxoethyl]anilino]-4-oxobutanoic acid Chemical compound N1([C@H](C(=O)N([C@H](CC=2C3=CC=CC=C3C=CC=2)C(N)=O)CC[C@H]1C)C=1C=C(C=CC=1)C(F)(F)F)C(=O)CC1=CC=C(NC(=O)CCC(O)=O)C=C1 PWBLNYLTLVRGNY-LCQPTLMKSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003800 Auricular swelling Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KLKWZMKGTIQLOG-UHFFFAOYSA-N [3-fluoro-5-(2-methylpropoxy)phenyl]boronic acid Chemical compound CC(C)COC1=CC(F)=CC(B(O)O)=C1 KLKWZMKGTIQLOG-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- OHDRQQURAXLVGJ-AXMZSLBLSA-N azane;(2z)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-AXMZSLBLSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 108010019249 cyclosporin G Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000043559 human ICAM1 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000005331 phenylglycines Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000002412 selectin antagonist Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000002345 steroid group Chemical group 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Description
DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS a The present invention relates to pharmaceutically active diazepanes.
In one aspect the present invention provides a compound of formula oO 0 R,
HN = 0) * N : N—4 I (N= oo e.g. including a compound of formula oO Oo R, wn = 0 28 he & ) wherein
R, is (Cq4)alkyl, e.g. methyl
R; is unsubstituted (Ci4)alkyl, e.g. methyl, or (Cy4)alkyl substituted by unsubstituted or substituted - (Ce.18)aryl, e.g. phenyl or - (Ce.18)aryl, e.g. phenyl, annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. which aryl or aryl annelated with heterocyclyl is one or morefold substituted by - halogen, . - halo(C.g)alkyl, - (Crs)alkoxy, . - cyano, - amino,
R; is (Ce.1g)aryl, e.g. phenyl, one or morefold substituted by - halogen,
- halo(C,.¢)alkyl, . - halo(C,.¢)alkoxy, - cyano, “ - phenyl, - heterocyclyl having § to 6 ring members and 1 to 4 heteroatoms selected from N, O, S, e.g. aromatic heterocyclyl, such as pyrimidinyl.
Preferably in a compound of formula - Ry is methyl, - Rais methyl or methyl substituted by - quinolinyl, - benzo[1,3]dioxolyl, - phenyl - phenyl one or morefold substituted by halogen, halo(C;_4)alkyl, (C,4)alkoxy, cyano, amino, dimethylamino, carboxy(C,.;)alkylcarbonylamino, amino(C,.z)alkylcarbonylamino, (C..4)alkylenecarbonylamino, heterocyclylcarbonyl(C,.z)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, such as piperazinyl, morpholinyl, - Rs is phenyl one or morefold, e.g. 1- to 3-fold, substituted by - halogen, - halo(C,.z)alkyl, e.g. CF; - halo(C;.o)alkoxy, e.g. OCF; - cyano, - phenyl, - heterocyclyl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms, such as pyrimidinyl. re In another aspect the present invention provides a compound of formula | wherein - Ry is methyl, . - R; is methyl substitued by quinolin-6-yl, - Rs is phenyl one or morefold, e.g. 1- or 2-fold, substituted by - halogen, e.g. fluoro, chloro, bromo; - halo(C,.2)alkyl, e.g. CFs,
- halo(C,_;)alkoxy, e.g. OCF, - phenyl, - aromatic heterocyclyl having 6 ring members and 2 nitrogen heteroatoms, e.g. pyrimidin-5-yl.
In another aspect the present invention provides a compound of formula | wherein - Ry is methyl, - Rz is methyl substituted by benzo[1,3]dioxol-5-yl, : - Rs is phenyl one or morefold, e.g. 1- or 2-fold, substituted by - halogen, e.g. fluoro or chloro; - halo(C,.p)alkyl, e.g. CF; - halo(C,)alkoxy, e.g. OCFj; - cyano. in another aspect the present invention provides a compound of formula | wherein - R; is methyl, - Rz is methyl substituted by phenyl or methyl substituted by phenyl! one or morefold, e.g. 1 to 3-fold, substituted by - halogen, e.g. chloro; - halo(C,.z)alkyl, e.g. CF; - (Cs2)alkoxy, e.g. methoxy; - cyano, - amino, - dimethylamino, - carboxy(C,.,)alkylcarbonylamino, - amino(C4_)alkylcarbonylamino, - ethenylcarbonyl amino - heterocyclylcarbonyl-(C,.,)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, S, preferably from N or. O, eg. piperazin-1-yl or morpholin-4-yl, : : - Rs is phenyl substituted one or morefold by - halogen, e.g. chloro or fluoro; - halo(C,.;)alkyl, e.g. CF; - halo(C,.2)alkoxy, e.g. OCF3; :
- cyano.
In another aspect the present invention provides a compound of formula | wherein . - Ry is methyl, - Ry is methyl, - Rs is phenyl substituted by halogen, e.g. chloro.
In another aspect the present invention provides a compound selected from the group consisting of - 2-[3~(3-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[3,5-cis-3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4- (quinolin-6-yl-acetyl)-{1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[5-Methyl-2-oxo-4-(quinolin-6-yl-acetyl)-3-(3-trifluoromethyl-phenyl)-[ 1 4]diazepan-1-yi]-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[3,5-cis-5-Methyl-2-oxo0-4-(quinolin-6-yl-acetyl)-3- (3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yi]-3-naphthalen-1-yl-propionamide, - 2-[3-(4-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yi)-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[3,5-cis-3-(4-Fluoro-phenyl)-5-methyl-2-oxo-4- (quinolin-6-yl-acety!)-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[3-(2-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yi}-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[3,5-cis-3-(2-Fluoro-phenyl)-5-methyl-2-oxo-4- (quinalin-6-yl-acetyl)-[1,4]diazepan-1-yi-3-naphthalen-1-yl-propionamide, - 2-[3~(3-Bromo-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, e.g. 2-[3,5-cis-3-(3-Bromo-phenyl)-5-methyl-2-oxo-4-(2- quinolin-6-yl-acetyl)-{1,4]diazepan-1-yl-3-naphthalen-1-yl-propionamide, - 2-[3-Biphenyl-3-yl-5-methyl-2-oxo0-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yi]-3- naphthalen-1-yl-propionamide, - 2-[3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-5-methyl-2-0x0-4- y (2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, - 2-[3-(3,5-Dichloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- . naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3,5-Dichloro-phenyl)-5-methyl-2-oxo- 4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yi-propionamide, - 2-[3-(4-Chloro-3-trifluoromethyl-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yi-acetyl)-
[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(4-Chloro-3- trifluoromethyl-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, - 2-[3-(3-Chloro-4-fluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1- yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-4-fluoro-phenyl)-5- methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yi]-3-naphthalen-1-yl-propionamide, - 2-[5-Methyl-2-ox0-4-(2-quinolin-6-yl-acetyl)-3-(2-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]- 3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-5-Methyl-2-oxo-4-(2-quinolin-6-yl- acetyl)-3-(2-triftuoromethyl-phenyl)-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[3-(3,4-Difluoro-phenyl)-5-methyl-2-oxo0-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3,4-Difluoro-phenyl)-5-methyl-2-oxo- 4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yi]-3-naphthalen-1-yl-propionamide, - 2-[3-(3-Cyano-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yi}-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Cyano-phenyl)-5-methyl-2-oxo-4- (2-quinolin-B-yl-acetyl)-[1,4]diazepan-1-yi}-3-naphthalen-1-yl-propionamide, - 2-{5-Methyl-2-0x0-3~(3-pyrimidin-5-yl-phenyl)-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]- 3-naphthalen-1-yl-propionamide, e.g. (R)-2-[5-Methyl-2-0x0-3-(3-pyrimidin-5-yl-phenyl)-4- (2-quinolin-6-yl-acetyl)-{1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[5-Methyl-2-ox0-4-(2-quinolin-6-yl-acetyl)-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1- yl}-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-5-Methyl-2-oxo0-4-(2-quinolin-6-yl- acetyl)-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-fluoro-phenyl)-5-methyl-2-oxo-{1,4]diazepan-1-yi]- 3-naphthalen-1-yi-propionamide, e.g. (R)-2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3,5-cis-3-(3- fluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1- yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2-Benzo[1,3]dioxol-5-yl-acetyl)- 3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yi]-3-naphthalen-1-yl-propionamide, - 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)- - [1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2-
Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-(1,4]diazepan-1- , yi]-3-naphthalen-1-yl-propionamide, - 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-4-fluoro-phenyl)-5-methyl-2-oxo-
[1.4ldiazepan-1-yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2- > Benzo[1 »3]dioxol-5-yl-acetyl)-3-(3-chloro-4-fluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1- yl]-3-naphthalen-1-yl-propionamide, . - 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-cyano-phenyi)-5-methyl-2-oxo-[1,4]diazepan-1-yi]- 3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2-Benzo[1 ,3]dioxol-5-yl-acetyl)-3- ) (3-cyano-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1 -yl-propionamide, - 2-[4~(2-Benzo[1 ,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3~(3-trifluoromethoxy-phenyl)- [1,4]diazepan-1-yi}-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-(2-
Benzo[1 ,3]dioxol-5-yl-acetyl)-5-methyl-2-ox0-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1- yl]-3-naphthalen-1-yl-propionamide, - 2-[3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-phenylacetyl-[1,4]diazepan-1-yl}-3-naphthalen-1- yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-phenylacetyl- [1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-[(3-trifluoromethyl-phenyl)-acetyl]-[ 1 ,4ldiazepan-1-. yll-3-naphthalen-1-yl-propionamide, e.g. (R)-2-{3,5-cis-3-(3-Fluoro-phenyl)-5-methyl-2-oxo- 4-[(3-trifluoromethyl-phenyl)-acetyl]-[ 1 ,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-{3-Biphenyl-4-yl-5-methyl-2-ox0-4-{2-(2,3,6-trichloro-phenyl)-acetyl)-[1 ,4)diazepan-1-yi}-3- naphthalen-1-yl-propionamide, e.g. 3,5-cis-2-{3-Biphenyl-4-yl-5-methyl-2-ox0-4-[2-(2,3,6- trichloro-phenyl)-acetyl]-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[4-[2~(4-Cyano-phenyi)-acetyl]-3-(3,4-difluoro-phenyl)-5-methyl-2-oxo-[1 /4]diazepan-1- yl}-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(4-Cyano-phenyl)-acetyl]-3- (3.4-difluoro-phenyl)-5-methyl-2-oxo-{1,4}diazepan-1-yl]-3-naphthalen-1-yl-propionamide, - 2-[3-(3-Chloro-phenyl)-4-[2-(4-cyano-phenyl)-acetyl]-5-methyl-2-oxo-[1 4ldiazepan-1-yl]-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(4-cyano- phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, - 2-{4-[2-(4-Amino-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1 ,4]diazepan-1-yi]-3- naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(4-Amino-phenyl)-acetyl]-3-(3- chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, . - 2-[4-{2-(4-Amino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1 ,4]diazepan- 1-yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-[2-(4-Amino-phenyl)-acetyl}-5- . methyl-2-oxo-3-(3-trifluoromethyl-phenyi)-[1,4]diazepan-1-yl]-3-naphthalen-1 -yl- propionamide, - 2-[4-[2-(4-Dimethylamino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyi-phenyl)-
[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, e.g. (R)-2-{(3S,5R)-4-[2-(4- . Dimethylamino-phenyl)-acetyl}-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1 ,4]diazepan-1- yll-3-naphthalen-1-yl-propionamide, : - 2-[4-[2-(3-Amino-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-{1,41diazepan-1-yl]-3- naphthalen-1-yl-propionamide, e.g. (R)}-2-[(3S,5R)-4-[2-(3-Amino-phenyl)-acetyl]-3-(3-
Y chloro-phenyl)-5-methyl-2-oxo0-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-7-methyl-3-oxo-2-(3-trifluoromethyl- phenyl)-[1,4]diazepan-1-yi}-2-oxo-ethyl}-phenyl)-succinamic acid, e.g. N-(4-{2-[(2S,7R)-4- ((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-7-methyl-3-oxo-2-(3-trifluoromethyl-phenyl)- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, - N-(4-{2-[4-(1-Carbamoyi-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, e.g. N-(4-{2-[(2S,7R)-4-((R)-1-
Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl}- 2-oxo-ethyl}-phenyl)-succinamic acid, - N-(3-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chioro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, e.g. N-(3-{2-[(2S,7R)-4-((R)-1-
Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl}- 2-oxo-ethyl}-phenyl)-succinamic acid, - 2-[4-{2-[4-(2-Amino-acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(3S,5R)-4-{2-{4-(2-Amino- acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo-{1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, - 2-[4-{2-[3-(2-Amino-acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, e.g. (R}-2-[(3S,5R)-4-{2-[3-(2-Amino- acetylamino)-phenyl]-acetyl}-3~(3-chloro-phenyl)-5-methyl-2-oxo-{1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, - 2-[4-{2-[4-(3-Amino-propionylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[(38,5R)-4-{2-[4-(3-Amino- - propionylamino)-phenyl}-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, - N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-acrylamide, e.g. N-(4-{2-[4-((R)-1-Carbamoyl-2- naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl}-2-oxo-ethyl}- phenyl)-acrylamide,
- N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- . [1,4]diazepan-1-yi]-2-oxo-ethyl}-phenyl)-4-morpholin-4-yl-4-oxo-butyramide, e.g. N-(4-{2- [(28,7R)-4-((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenytl)-7-methyl-3-oxo- . [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-morpholin-4-yl-4-oxo-butyramide, - N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methy}-3-oxo- [1,4]diazepan-1 -yl]-2-oxo-ethyl}-phenyl)-4-oxo-4-piperazin-1 -yl-butyramide, e.g. N-(4-{2- [(2S,7R)-4-((R)-1-Carbamoyl-2-naphthalen-1-yi-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-oxo-4-piperazin-1-yl-butyramide, - 2-{3-(3-Chloro-phenyl)-4-[2-(2-methoxy-phenyl)-acetyl}-5-methyl-2-oxo-[1,4]diazepan-1-yl}- 3-naphthalen-1-yl-propionamide, e.g. (R)-2-{(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(2-methoxy- phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-{3-(3-Chloro-phenyl)-4-[2-(4-methoxy-phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl}- 3-naphthalen-1-yl-propionamide, e.g. (R)-2-{(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(4-methoxy- phenyl)-acetyl}-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, - 2-[4-[2-(3-Chloro-4-methoxy-phenyl)-acetyl}-(3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-{(3S,5R)-4-[2-(3-Chloro-4- methoxy-phenyl)-acetyl}-(3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, - 2-[4-Acetyl-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepam-1-yl}-3-naphthalen-1-yl propionamide, e.g. (R)-2-[(3S,5R)-4-Acetyl-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepam-1-yl]-3-naphthalen-1-yl propionamide,
In another aspect the present invention provides a compound of formula | which is a compound of formula
Cl oO O
HN 0 0] 2 \ y * y 7 . . { ( \ 0 ~~ rer e.g. including the compound a 0 O N : ww PN 0 0 _*—N N 7 hs ”
In another aspect the present invention provides (R)-2[(3S,5R)-4-(2-Benzo[1,3]dioxol-5-yl- acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepam-1-yl}-3-naphthalen-1-yl- propionamide.
If not otherwise defined herein - alkyl includes linear or branched (C,s)alkyl, such as (Ci4)alkyl, e.g. (Cq5)alkyl, including unsubstituted or substituted alkyl, e.g. alkyl substituted by groups which are conventional in organic chemistry, e.g. halogen, OH, NH; or halo(C,¢)alkyl, - haloalkyl includes halo(C.g)alkyl, such as halo(Ci4)alkyl, e.g. halo(C.2)alkyl, wherein one or more halogen(s) is (are) present in the alkyl group, preferably —CFs, - halogen includes fluoro, chloro, bromo, iodo, e.g. fluoro, chloro, bromo, preferably fluoro or chloro, - amino includes unsubstituted and substituted amino, e.g. amino substituted by (Cy4)alkylamino, di(C4)alkylamino and amino substituted by acy, - acyl includes acyl, having 1 to 12 carbon atoms altogether, e.g. carboxy(C,_4)alkylcarbonyl, such as carboxy(C,.s)alkylcarbonyl, amino(C,4)alkylcarbonyl, such as amino- (C,5)alkylcarbonyl, (C.4)alkenylcarbonyl or heterocyclylcarbonyl(C,4)alkylcarbonyl, wherein heterocyclyl has 5 or 6 ring members and 1 to 4 heteroatoms, preferably 1 or 2 heteroatoms, selected from N, O, S, preferably N, O, e.g. piperazinyl or morpholinyi, ) - heterocyclyl includes heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, preferably N, O, such as alicyclic and aromatic heterocyclyl, e.g. ) heterocyclyl having 6 ring members and 1 to 2 heteroatoms selected from N, O, e.g. piperazinyl, morpholinyl, pyrimidinyl, - aryl includes (Ce.1s)aryl, e.g. phenyl, and (Ce.1s)aryl, e.g. phenyl, annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, preferably N, O,
e.g. heterocyclyl having 5 ring members and 2 heteroatoms selected from N, O, preferably v benzo(1,3)dioxol-4-yl, benzo(1,3)dioxol-5-yl,quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl.
Compounds provided by the present invention, e.g. including compounds of formula |, |, lerer and I'prer are hereinafter designated as "compound(s) of (according to) the present invention". Each single substituent defined above in a compound of the present invention may be per se a preferred substituent, independently of the other substituents defined.
A compound of the present invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and in the form of a solvate. A compound of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa. A compound of the present invention in free form or in the form of a salt and in the form of a solvate may be converted into a corresponding compound in free form or in the form of a salt in unsolvated form; and vice versa.
In another aspect the present invention provides a compound of the present invention in the form of a salt.
A salt of a compound of the present invention includes a pharmaceutically acceptable salt, e.g. including a metal salt or an acid addition salt. Metal salts include for example alkali or earth alkali; acid addition salts include salts of a compound of formula | with an acid, e.g. acetic acid, trifluoroacetic acid, hydrochloric acid.
A compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans isomers. A compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form of y diastereoisomeres and mixtures thereof or enantiomers or mixtures thereof, e.g. racemates.
For example the groups R,, R; and the group naphthylmethyl in position * in a compound of . formula | may be in the (R)- or in the (S)-configuration, e.g. including mixtures therof.
Preferably the naphthyimethyl group and R, in a compound of formula | both are in the (R)- configuration and Rj is in the (S)-configuration. Isomeric mixtures may be separated as appropriate, e.g. according, such as analogously, to a method as conventional, to obtain pure isomers. The present invention includes a compound of the present invention in any . isomeric form and in any isomeric mixture.
Similar considerations apply in relation to starting materials exhibiting isomeric features, e.g. : analogously as indicated above.
Any compound described herein, e.g. a compound of the present invention, may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g. or as specified herein. Starting materials are known or may be prepared according, e.g. analogously, to a method as conventional or as described herein.
In another aspect the present invention provides a process for the preparation of a compound of the present invention comprising
A) reacting a compound of formula
Oo 0 Ry *—N NH > ol {
O wherein R; and R; are as defined above, with a compound of formula 0]
Ho—4{ 1
R, e.g. in a protected form, e.g. in the presence of a - condensing agent, e.g. a carbodiimide - abase, e.g. an amine, such as diidopropylethylamine or dimethylaminopyridine, ’ in organic solvent, e.g. polar organic solvent, such as N,N-dimethylformamide, optionally deprotecting, and optionally further reacting, to obtain a compound of formula | and isolating a compound of formula |,
OR
B) reacting a compound of formula
Br . 0 Q . 0
HN" r—N N—4 0 wherein R, and R; are as defined above, with an optionally substituted compound of formula
B(OH), B(OH), 0) Va or (a) Vg wherein A denotes an aromatic heterocyclyl having 5 (n=1) or 6 (n=2) ring members and 1 to . 4 heteroatoms selected from N, O, S, e.g. in the presence of a catalyst, e.g. Pd(PPhs)s, to obtain a compound of formula | wherein R; is phenyl substituted by optionally substituted phenyl or aromatic heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, and isolating a compound of formula | obtained from the reaction mixture.
An optionally protected group R; of formula lll e.g. includes phenyl substituted by an amine.
Such amine may be protected by an appropriate protection group, e.g. including tert- butoxycarbony! (Boc), which protecting group may be removed after reaction of a compound of formula Il with a compound of formula 111 to obtain a free amine group. Further reacting e.g. includes alkylating or acylating such amine group as appropriate, e.g. according, e.g. analogously, to a method as conventional.
In an intermediate of formula 11 or of formula IV (starting materials), functional groups, if present, optionally may be in protected form or in the form of a salt, if a salt-forming group is present. Protecting groups, optionally present, may be removed at an appropriate stage, e.g. according, e.g. analogously, to a method as conventional :
A compound of formula | thus obtained may be converted into another compound of formula : l, e.g. or a compound of formula | obtained in free form may be converted into a salt of a compound of formula | and vice versa.
In another aspect the present invention provides ". -a compound of formula Il wherein Ry and Rj are as defined above, and - a compound of formula IV, wherein R; and R; are defined as above, e.g. useful as intermediates for the production of a compound of the present invention.
The above reaction A) is a an amine acylation reaction and may be carried out as appropriate, e.g. according, e.g. analogously, to a method as conventional or as described herein. The above reaction B) is a cross coupling reaction and may be carried out as appropriate, e.g. according, e.g. analogously, to a method as conventional or as described herein.
Any compound described herein, e.g. a compound of the present invention and intermediates of formula Ii and IV, may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g. or as specified herein.
The compounds of the present invention exhibit valuable pharmacological properties, e.g. by mediating, such as inhibiting, the activity of LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or
LFA-1/JAM-1 interactions and thus mediating, e.g. inhibiting inflammation, e.g. as indicated in in vitro and in vivo TEST SYSTEMS herein and are therefore indicated for therapy.
A. Invitro TEST SYSTEM: (Cell free assay)
The assay determines the binding of soluble human ICAM-1 to immobilized human LFA-1.
LFA-1 is purified from JY cells, a human lymphoblastoid B cell-line, by immunoaffinity chromatography analogously as described by Dustin et al., J. Immunol. 148, 2654-2663, 1992. ICAM-1 mouse Cx fusion protein (ICAM-1) is produced using the baculovirus system : as described by Weitz-Schmidt et al., Anal. Biochem. 238,184-190, 1996.
Purified LFA-1 is diluted 1:20 in phosphate buffered saline (PBS) containing 2 mM MgCl, pH . 7.4 and coated onto microtiter plates (Nunc) at 37° for 3 hours. Plates are blocked with 1% heat-treated bovine serum albumin in PBS for 2 hours at 37° followed by a washing step using PBS, 2 mM MgCl, 1% fetal calf serum, pH 7.4 (assay buffer). Compounds of the present invention (10 mM solution in DMSO) are diluted in assay buffer and added to the plates. Biotinylated recombinant ICAM-1 in assay buffer (6 pg/ml) is added and allowed to bind at 37° for one hour. After incubation, wells are washed with assay buffer. Streptavidin- - peroxidase diluted 1:5000 in assay buffer is added and incubated for 45 min at 37°. Plates : are washed with assay buffer and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt substrate solution is added to each well. The reaction is stopped after 20 minutes and bound ICAM-1 is determined by measuring the optical density at 405 nmin a microplate reader.
In this assay the compounds of the present invention exhibit activity, e.g. the compounds of the present invention inhibit adhesion of LFA-1 to ICAM-1 with an ICs, < 50 uM, preferably 0.05 to 50 pM. The compounds of examples 13 and 14 are preferred compounds of the present invention and show ICs, values of 0.43 or 0.09 uM, respectively, in this assay.
We have surprisingly found that compounds of formula I, wherein R; is substituted phenyl . show higher ICs, values in such LFA-1 in vitro TEST SYSTEM than compounds of formula |, wherein Rj; is unsubstituted phenyl.
B. In vivo TEST SYSTEM: Allergic Contact Dermatitis (ACD)
Groups of 8 female NMRI mice are sensitized on the shaved abdomen with 50 pl of oxazolone (2% in acetone) and challenged with 10 ul of 0.2% oxazolone on the inner surface of the right ear 7 days later. The unchallenged left ears serve as normal controls and dermatitis is evaluated from the individual differences in auricular weights, which are taken as a measure of inflammatory swelling 24 hours after the challenge. Dermatitis is evaluated in test- and control groups. The test groups are treated with the test compounds orally (2 hours after challenge), the controls are treated similarly with the vehicles alone. For oral administration the compounds are administered in an oil in H,O emulsion. The data of the test- and the vehicle-treated control groups are statistically analysed by ANOVA followed by
Dunnet T-test (normal distribution or data) or by H and U-test, respectively. When administered p.o. at a dose of from 0.03 to 30 mg/kg, the compounds of the present invention inhibit the elicitation phase of allergic contact dermatitis. For example, compound of Example 14 has an inhibiting effect in this assay of >30% when administered p.o. at a dose of 0.03 mg/kg.
The compounds of the present invention are therefore expected to be useful in the treatment of diseases or disorders mediated by interactions of LFA-1 with its ligands involved in cell adhesion, migration and activation. The compounds may be preferably useful for treatment of inflammatory conditions, allergic diseases or autoimmune diseases. Examples are - inflammatory injuries of the skin (psoriasis, eczemas, urticaria, acne, pyoderma gangrenosum, sun burns or toxic epidermal necrolysis), lung (adult respiratory distress ‘ syndrome, COPD), kidney (acute/chronic interstitial/glomerulonephritis), liver (acute/chronic hepatitis, granulomatous diseases), cardiovascular system (ischemia/reperfusion injuries, shock, arteriosclerosis, vasculitides), eye (conjunctivitis, keratitis) or gastrointestinal tract (Crohn's disease, ulcerative colitis). Examples of allergic conditions are allergic contact dermatitis, atopic dermatitis or asthma. Rheumatoid arthritis, multiple sclerosis, (systemic) lupus erythematosus, Sjogren’ syndrome, alopecia areata, uveitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa or myasthenia gravis are examples of auto-immune mediated conditions.
The compound of the present invention may also be used for prevention of acute and chronic rejection of allo- or xenografts, transplantation, host vs. graft or graft vs. host diseases, for the treatment of neoplastic diseases including metastasis of neoplastic or cancerous growth or cancer, AIDS and infectious diseases.
Treatment includes prophylaxis.
The compound of the present invention may be preferably useful for treatment of psoriasis, rheumatoid arthritis, inflammatory bowel diseases (Crohns disease, ulcerative colitis), - (systemic) lupus erythematosus, atopic dermatitis, Sjogren syndrom, rejection after transplantation and graft vs. host disease.
In one preferred aspect the compounds of the present invention are useful in the treatment of autoimmune diseases, e.g. rheumatoid arthritis, or of inflammatory diseases, e.g. psoriasis or atopic dermatitis, such as rheumatoid arthritis.
For the above uses the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, satisfactory results are indicated to be obtained systemically at daily dosages of a compound of the present invention from about 0.1 mg/kg to about 100 mg/kg body weight. An indicated daily dosage in the larger mammals, e.g. humans, is in the range from about 0.5 mg to about . 500 mg (e.g. about 0,00625 mg/kg to about 6,25 mg/kg), conveniently administered, for example, in divided doses up to four times a day or in retard form.
The compounds of the present invention may be administered systemically or topically, by . any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a " suppository form. Percutaneous administration via patches or other delivery systems may also be a possible route for prophylaxis or treatment of above diseases.
For topical use, e.g. including administration to the eye, satisfactory results may be obtained with local administration of a 0.5-10 %, such as 1-3% concentration of active substance several times daily, e.g. 2 to 5 times daily.
In another aspect the present invention provides a compound of the present invention for use as a pharmaceutical, e.g. against diseases as indicated above, such as rheumatoid arthritis.
For pharmaceutical use a compound of the present invention includes one or more, preferably one, compounds of the present invention, e.g. a combination of two or more compounds of the present invention.
In another aspect the present invention provides the use of a compound of the present invention for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of a disease as indicated above, for example of diseases mediated by LFA- 1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions, e.g against inflammatory diseases, allergic conditions or autoimmune diseases, such as autoimmune diseases, e.g. psoriasis, asthma or rheumatoid arthritis.
In another aspect the present invention provides a pharmaceutical composition comprising a compound of the present invention in association with at least one pharmaceutically acceptable excipient, e.g. including a carrier and/or diluent, e.g. including fillers, binders, . disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating : osmotic pressure and/or buffers.
Such compositions may be manufactured according, e.g. analogously, to a method as conventional, e.g. by mixing a compound of the present invention with a pharmaceuticaily acceptable excipient, e.g. a carrier and/or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 1000 mg (e.g. from about 0.00125 mg/kg to about 12.5 mg/kg), e.g. 0.5 mg to 500 mg, such as e.g. 1 mg to about 125 mg of a compound of the present invention.
The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt, e.g. an acid addition salt or metal salt; or in free form, optionally in the form of a solvate. The compounds of the present invention in the form of a salt exhibit the same order of activity as the compounds of the present invention in free form; optionally in the form of a solvate.
In another aspect the present invention provides: - A method for treatment of disorders or diseases mediated by LFA-1/ICAM-1,
LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions, e.g. such as indicated above, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of the present invention; and - A method for treatment of diseases as indicated above, e.g. inflammatory, allergic or autoimmune diseases, e.g. as indicated above, e.g. psoriasis, asthma, rheumatoid arthritis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of the present invention.
For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmakokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.01 g to about 1.0 g (e.g. from about 0,125 mg/kg to about 12,5 mg/kg), of a compound of the present invention; conveniently administered, for example, in divided doses up to four times a day. : A compound of the present invention may be administered by any conventional route, for example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. : including intravenous, intramuscular, subcutanous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration; e.g. in form of coated or uncoated tablets, capsules, injectable solutions or suspensions, e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams,
tinctures, lip sticks, drops, sprays, or in the form of suppositories.
A compound of the present invention may be used for pharmaceutical treatment according to : the present invention alone or in combination with at least one, e.g. one or more, other pharmaceutically active agents. Such other pharmaceutically active agents e.g. include ) compounds active in immunomodulating regimens or other anti-inflammatory agents, e.g. for the treatment or prevention of inflammatory or allergic conditions, autoimmune disorders, or acute or chronic rejection of allo- or xenograft. For example, compounds of the present _ invention may be used in combination with cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, ASM 981, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin etc., corticosteroids, cyclophosphamide, azathioprene, methotrexate, FTY 720, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualine, immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25,
CD28, B7, CD40, CD45, or CD58 or their ligands, or other immunomodulatory compounds, e.g. CTLA4lg, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including selectin antagonists and VLA-4 antagonists.
Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instructions for co- administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instructions for simultaneous or sequential administration are given.
If the compounds of the present invention are administered in combination with other immunosuppressive/immunomodulatory or anti-inflammatory active agents, e.g.for preventing or treating acute or chronic rejection or inflammatory or autoimmune disorders as . hereinabove specified, dosages of the co-administered immunosuppressant, immunomodulatory or anti-inflammatory compound will of course vary depending on the type - of co-drug employed, e.g. whether it is a steroid or a cyclosporin, on the specific drug employed, on the condition being treated and so forth. In general comparable dosage ranges as indicated for the co-administration may be are appropriate.
In another aspect the present invention provides a pharmaceutical composition according to : the present invention, further comprising another pharmaceutically active agent. ’ In another aspect the present invention provides - A method for treatment of disorders or diseases as indicated above comprising } co-administrating, e.g. concomitantly or in sequence, a therapeutically effective amount of at least one compound of the present invention and at least one second pharmaceutically active agent, said pharmaceutically active agent being selected from the group consisting of immunosuppressants, immunomodulatory or anti-inflammatory active agents, e.g. such as indicated above; and - A pharmaceutical combination, e.g. a kit, for use in a method for treatment according to the present invention, comprising at least one compound of the present invention to be used concomitantly or in sequence with at least one immunosuppressant, immunomodulatory or anti-inflammatory active agent. The kit may comprise instructions for concomitant administration or administration in sequence.
In another aspect the present invention provides a compound of formula
Oo 0 Rap
HN »—( 8] — A (Vw oT wherein
Rp is (Ci4)alkyl,
Rap is (Ci4)alkyl or —(CH2),-R4p, Wherein nis1, 2,3 or4 and
R4p is unsubstituted or substituted } - phenyl or - phenyl annelated with another ring system, which other ring system is a 5- or ’ 6-membered heterocycle, having one to 4 heteroatoms selected from N, O, S, e.g. wherein substituents are selected from the group consisting of - halogen, - unsubstituted amino or amino substituted by one or two (C;4)alkyl,
- cyano, - (Cy4)alkoxy, - (Cy.¢)haloalkyl and : Rap is substituted phenyl, e.g. one or morefold, wherein the substituents are selected from the group consisting of - halogen, - (Ci.g)haloalkyl, - unsubstituted or substituted phenyl, wherein substitutents are as indicated under “substituted phenyls” in the meaning of Rp, €.g. in the form of a salt and/or solvate.
In the following examples all temperatures are in degree (°) Celsius. In the reaction schemes and corresponding description R; and R; are as defined above.
The following ABBREVIATIONS are used:
AcOH acetic acid Boc tert.-butoxy-carbonyl
DBU 1,4-diaza-bicyclo[5.4.0lundec-7-en DIEA diisopropylethylamine
DIPCI diisopropylcarbodiimide DMAP N,N-dimethyl-4-aminopyridine
DMF N,N-dimethylformamide EtAc ethyl acetate equiv. equivalent EX example
HOAt 1-hydroxy-7-azabenzotriazole i-PrOH isopropanol
MeOH methanol NMM N-methyl-morpholine it room temperature THF tetrahydrofurane
TFA trifluoroacetic acid TsOH p-toluenesulfonic acid
Z benzyloxycarbonyl
EDC N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide
EDC-HCI N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide in the form of a hydrochloride
: PROCEDURE A
Synthesis of compounds of the present invention ) Aa. Synthesis of a ketal intermediate . 0) (0)
H,N HN H »—NH, »—N 0 Ne & OL
A1 A2
Naphthylalanine amide of formula A1 and 0.3 equiv. of NMM are dissolved in dioxane and 1.5 equiv. of methylvinylketone are added. The mixture obtained is stirred at RT for 15 hours and 5 equiv. of 2-methoxydioxolane and 1.5 equiv. of TsOH-monohydrate are added. The mixture obtained is stirred and diluted with EtAc. The organic phase obtained is washed and dried, solvent is evaporated and a ketal intermediate of formula A2 is obtained, which is optionally purified or used without further purification.
Ab. Amine-protection of phenylglycines
Ry R, —_—
HOOC— Phe-gly HOOC— A3
NH, NHBoc
A compound of formula Phe-gly, wherein R; is as defined above, is dissolved in MeOH. 2 equiv. of NaHCO3 and 1.2 equiv. of Boc-anhydride are added to the solution obtained and the suspension obtained is heated at 50° under stirring. From the mixture obtained solvent is evaporated and H,O and toluene are added. The phases obtained are separated and the : organic phase obtained is extracted with 1N NaOH. The pH of the aqueous phase obtained is adjusted to pH 3 and the mixture obtained is extracted with EtAc. The organic phase - obtained is dried, solvent is evaporated and racemic Boc-phenylglycine of formula A3, wherein R; is as defined above, is obtained.
Ac. Amine acylation
R, 0 O
HN - . 7 * N NHBoc
Compound of formula A2 —> CY Syn A4 0 aN 1 equiv. of a compound of formula A2, wherein R; is as defined above, 1.5 equiv. of racemic (substituted) Boc-phenyiglycine of formula A3, wherein R; has the meaning as indicated above, and 0.12 equiv. of HOA are dissolved in DMF. 1.5 equiv. of DIEA and 1.5 equiv. of
EDC in free base form are added during 15 hours at rt. Solvent is evaporated, the evaporation residue obtained is diluted with EtAc and extracted with 1N HCI and 5%
NaHCO; solution. The organic phase obtained is dried and solvent is evaporated. A compound of formula A4, wherein R; is as defined above, is obtained in the form of a diastereoisomeric mixture.
Ab. Deprotection and reductive ring closure
Rs 0 Oo
H,N -
YL
Compound of formula A4 —> a CH,
AS
A compound of formula A4, wherein R; is as defined above, is dissolved in TFA/H.O at 0°,
The mixture obtained is stirred, quenched with H,O and solvent is evaporated. A diastereoisomeric mixture of a compound of formula A4, wherein the Boc-NH- group is deprotected is obtained and is dissolved in MeOH/H,0. The pH of the mixture obtained is adjusted to pH 5. 0.5 equiv. of a NaCNBH;-solution in MeOH/HO are added at 0° to the mixture obtained, the mixture obtained is stirred, solvent is evaporated and the evaporation residue obtained is diluted with EtAc.3.5M phosphate-buffer of pH 4 are added to the mixture obtained, two phases are obtained and are separated. The organic phase obtained is : extracted with 5% NaHCO; solution, dried and solvent is evaporated. A compound of formula
AS5, wherein Rj is as defined above, is obtained.
Ae. Acylation of diazepanes < Rs 0 Oo
HN LO
— wd ot gd
Compound of formula AS ——— a CH,
AB
A compound of formula A5, wherein R; is as defined above, is treated with 1.7 equiv. of
R>COOH, wherein R; is as defined above, 1.3 equiv. of DIEA and 0.2 equiv. of HOAt in
DMF. The mixture obtained is heated to 35° and 1.7 equiv. of EDC are added and the mixture obtained is stirred for 15 hours at 35°. From the mixture obtained solvent is evaporated, the evaporation residue obtained is dissolved in EtAc and extracted with 1N HCI and 5% NaHCO; solution. The organic phase obtained is dried and solvent is evaporated. A compound of formula A6 is obtained, which is optionally subjected to chromatography (e.g. silica gel, toluene/i-PrOH), in order for further purification, if desired.
PROCEDURE B
The compound of example 22 is treated with 1.5 equiv. of N-Boc-beta-alanine, or N-Boc- glycine, respectively, 1.5 equiv. of EDC-HCI and 0.5 equiv. of DMAP in DMF at rt. The mixture obtained is diluted with EtAc and 1N HCI, two phases are obtained and are separated, the organic phase obtained is washed, dried and solvent is evaporated. The evaporation residue obtained is dissolved in TFA/H,0 at 0°, stirred, diluted with dioxane and solvent is evaporated. A residue obtained is subjected to RP-chromatography. The compounds of example 31 and example 29, respectively, in the form of a trifluoroacetate are obtained. When using the compound of example 25 and N-Boc-glycine, the compound of example 30 is obtained.
PROCEDURE C
The compound of example 31 is treated with an excess of CHJ in CH,Cl./K,CO3 at rt. From the mixture obtained solvent is evaporated, the evaporation residue obtained is dissolved in
MeOH/H,O and worked up by solid-phase extraction (C-18 cartridge, MeOH/H,O gradient). » The compound of example 32 is obtained.
PROCEDURE D
; The compound of example 22, or example 23, respectively, is treated with succinic acid anhydride. Depending on the starting materials, the compound of example 27, or example 27, respectively, is obtained.
PROCEDURE E
The compound of example 27 is treated with 6 equiv. of morpholine and 2 equiv. of EDC-HCI in DMF at 0° for 4 hours at pH 8 (adjustment by addition of TFA). The mixture obtained is diluted with EtAc and 1N HCI, two phases obtained are separated, the organic phase obtained is washed, dried and solvent is evaporated. The compound of example 33 is obtained.
PROCEDURE F
The compound of example 27 is treated with 6 equiv. of piperazine and 2 equiv. of EDC-HCI in DMF at pH=8 (pH-adjustment by addition of TFA). The mixture obtained is diluted with
EtAc and 5M pH 4 phosphate buffer, two phases obtained are separated, the organic phase obtained is washed, dried and solvent is evaporated. The compound of example 34 is obtained.
PROCEDURE G
The compound of example 5 is treated with phenylboronic acid, or pyrimidine-5-boronic acid, respectively, in the presence of a catalytic amount of palladium tetrakistriphenylphosphine in dimethoxyethane/ageous Na,COs-solution (6:1) at 130° for 10 minutes in a closed vessel.
The mixture obtained is diluted with EtAc, extracted at pH 4 with phosphate buffer and aqueous NaxCOj; solution, and, from the organic layer obtained, solvent is evaporated.
Depending on the boronic acid used, a compound of example 6, or 12b, respectively, is obtained. A compound of example 6 is treated with trifluoroacetic acid and the compound of example 6 is obtained in the form of a trifluoroacetate. . Analogously to procedures as described above, but using appropriate starting materials, compounds of formula | wherein R, is methyl and R; and R; are as defined in TABLE 1 : below are obtained.
The compounds of examples - 1-5, 7-25, 27-28 and 35-38 are prepared according to procedure A; - 6 and 12b are prepared according to procedure G;
- 26 and 27 are prepared according to procedure D; : : - 29-31 are prepared according to procedure B,; - 32 is prepared according to procedure C; " - 33 is prepared according to procedure E; - 34 is prepared according to procedure F
The compounds of examples 6, 11, 23, 25, 29 and 31 are obtained in the form of a trifluoroacetate.
Under "DATA" in TABLE 1 there are also indicated - Ry values (thin layer chromatography on silica gel 60, in toluene/fi-PrOH 1:1 (=T) or EtAc (=E); - "H-NMR data in CDCls, unless otherwise indicated.
TABLE 1 [1 - F R=0.55 (T). 5 = 8.84 (dd, 4Hz, 1Hz),
N 8.82 (dd), 8.11 (d, 9Hz), 8.07 (d, 8Hz), 8.00 (d, 9Hz), 7.97 (d, 9Hz), 7.90 (d,
Z 8Hz), 7.83 (d, 8Hz), 7.76 (d, 8Hz), 7.54
N (m), 7.29 (m), 7.20 (dd, 8Hz, 4Hz), 7.06 (d, 8Hz), 6.99 (d, 9Hz), 6.59 (d, 8Hz), 6.54 (s), 6.38 (s br, NH), 6.29 (s br, NH), 6.05 (s), 5.62 (dd, 8Hz, 8Hz), 5.48 (dd, 7Hz, 7Hz), 5.38 (s br, NH), 4.62 (m), 4.00 (d, 15Hz), 3.88 (d, 15Hz), 2.78 (dd, 13Hz, 12Hz), 0.62 (d, 7HZz), 0.59 (d, THz
Pp) CF, R=0.37 (T); 5 = 8.81 (dd, 4Hz, 1Hz),
NX 8.01 (d, 9Hz), 7.99 (d, 9Hz), 7.91 (d, 8Hz), 7.04 (d, 8Hz), 6.83 (s), 6.02 (s),
N 5.70 (dd, 9Hz, THz), 5.49 (dd, THz, 7Hz), 4.60 (m), 4.02 (d, 15Hz), 3.93 (d, 15Hz), 2.87 (dd, 13Hz, 11Hz), 0.57 (d, 7Hz), 0.50 (d, 7Hz 3 F R=0.65 (T). 5 = 8.84 (dd, 4Hz, 2Hz),
N 8.11 (d, 9Hz), 8.07 (d, 8Hz), 8.00 (d, 9Hz), 7.97 (d, 9Hz), 7.90 (d, 7Hz), 7.83
N° (d, 8Hz), 7.76 (d, 8Hz), 7.64 (m), 7.55 (m), 7.41 (m), 7.00 (dd, 9Hz, 9Hz), ’ 6.79 (m), 6.54 (s br), 6.30 (s br), 6.04 (s), 5.63 (dd, 8Hz, 8Hz), 5.49 (dd, 7Hz, 7Hz), 5.40 (s br), 4.61 (m), 3.99 (d, : 15Hz), 3.87 (d, 15Hz), 2.78 (dd, 13Hz, 11Hz), 0.59 (d, 7Hz), 0.54 (d, 7Hz 4 F R=0.60 (T). 8 = 8.83 (dd, 4Hz, 1Hz),
N 8.74 (dd, 4Hz, 1Hz), 8.11 (d, 9Hz), _ 8.02 (d, 9Hz), 7.96 (d, 9Hz), 7.89 (d,
N 8Hz), 7.81 (d, 8Hz), 7.75 (d, 8Hz), 6.56 s br), 6.21 (s), 5.55 (dd, 8Hz, 8Hz),
EX] RT "Ry | DATA . 5.52 (dd, 7Hz, 7Hz), 5.42 (s br), 5.38 (s br), 4.62 (m), 3.95 (d, 15Hz), 3.83 (d, 15Hz), 3.55 (dd, 16Hz, THz), 3.45 (dd, 15Hz, 8Hz), 3.30 (dd, 13Hz, 11Hz), 3.19 (dd, 15Hz, 8Hz), 2.81 (dd, 13Hz, 12Hz), 1.84 (ddd, 15Hz, THz, 7Hz), . 0.56 (d, 7Hz), 0.54 (d, THz
Br R=0.32 (T). 5 = 8.84 (dd, 4Hz, 2Hz),
N 8.15 (d, 8Hz), 8.10 (d, 8Hz), 8.01 (d,
P 8Hz), 8.00 (d, 8Hz), 7.91 (d, 8Hz), 7.85
N (d, 8Hz), 7.77 (d, 8Hz), 7.69 (s), 7.66 (s), 7.63 (dd, 7Hz, 8Hz), 7.55 (dd, 8Hz, 8Hz), 7.42 (m), 7.35 (dd, 4Hz, 8Hz), 7.29 (d, 8Hz), 7.19 (d, 7Hz), 6.99 (dd, 8Hz, 8Hz), 6.78 (s), 6.74 (d, 8Hz), 6.54 (s br), 6.30 (s br), 6.01 (s), 5.63 (dd, 8Hz, 8Hz), 5.48 (dd, THz, THz), 5.43 (s br), 5.35 (s br), 4.62 (m), 4.01 (d, 15Hz), 3.92 (m), 3.89 (d, 16Hz), 3.69 (dd, 15Hz, 8Hz), 3.65 (d, 16Hz), 3.54 (dd, 15Hz, 8Hz), 3.42 (dd, 15Hz, 8Hz), 3.41 (dd, 15Hz, 9Hz), 3.34 (dd, 12Hz, 11Hz), 2.78 (dd, 13Hz, 11Hz), 1.86 (ddd, 15Hz, 6Hz, 6Hz), 0.63 (d, 7H2), 0.58 (d, 7Hz
R=0.34 (T 4:1). 6 = 9.15 (dd, 5Hz, ~ 1Hz), 9.09 (dd, 5Hz, 1Hz), 8.66 (d, 8Hz), 8.47 (d, 9Hz), 8.42 (d, 9Hz), 8.42
No (d, 8Hz), 8.02 (d, 8Hz), 7.98 (d, 9Hz), 7.97 (s), 7.93 (d, 7Hz), 7.91 (s), 7.67 (dd, 12Hz, 1Hz), 7.65 (dd, 13Hz, 1Hz), 7.60 (m), 7.50 (ddd, 8Hz, 8Hz, 3Hz), 6.99 (d, 7Hz), 6.94 (s), 6.91 (s br), 6.62 (s br), 6.57 (s br), 6.18 (s), 5.67 (dd,
THz, 7Hz), 5.60 (dd, 7Hz, 7Hz), 4.59 (m), 4.02 (d, 16Hz), 3.94 (d, 17Hz), 3.91 (s), 3.88 (m), 3.74 (dd, 15Hz, 7Hz), 3.53 (dd, 15Hz, 9Hz), 3.39 (dd, 12Hz, 12Hz), 3.03 (dd, 13Hz, 12Hz), 0.69 (d, 7Hz), 0.63 (d, THz 7 NN R=0.45 (T 4:1). 5 = 8.84 (m), 8.12 (d, 9Hz), 8.07 (d, 8Hz), 8.00 (d, SHz), 7.97 _ (d, 9Hz), 7.90 (d, 8Hz), 7.83 (d, 8H),
N ca | 7.76 (d, 9Hz), 7.04 (dd, 8Hz, 8Hz), 6.69 (s), 6.68 (s), 6.57 (s br), 8.33 (s . br), 5.62 (dd, 8Hz, 8Hz), 5.48 (dd, 7Hz, 7Hz), 4.61 (m), 4.00 (d, 15Hz), 3.92 (m), 3.89 (d, 15Hz), 2.78 (dd, 11Hz, 12Hz), 0.62 (d, THz), 0.58 (d, 7Hz
[EX | RR TR [pata . | R=0.60 (T). 6 = 8.84 (dd, 4Hz, 2Hz),
N 7.98 (d, 9Hz), 7.89 (d, 8Hz), 7.85 (d, 8Hz), 7.76 (d, 8Hz), 7.53 (m), 7.41 (dd, . N THz, 7Hz), 7.28 (m), 7.17 (s), 7.17 (s), 7.13 (m), 6.53 (s), 6.49 (s br), 6.29 (s br), 5.91 (m), 5.60 (dd, 8Hz, 8Hz), 5.57 . Cl (s br), 5.45 (s br), 5.44 (dd, 7Hz, THz), 4.62 (), 4.01 (d, 15Hz), 3.97 (m), 3.90 (d, 16Hz), 3.41 (dd, 15Hz, THz), 2.78 (dd, 13Hz, 11Hz), 1.91 (m), 0.68 (d, 7HZz), 0.62 (d, 7Hz
NN CF, R=0.55 (T). 5 = 8.78 (dd, 4Hz, 2Hz), o | 797 (d, 8Hz), 7.88 (d, 9Hz), 7.83 (d, _ 7Hz), 7.81 (d, 7Hz), 7.69 (d, 9Hz), 7.57
N (s), 7.52 (s), 7.47 (dd, 7Hz, 8Hz), 7.23 (d, 7Hz), 7.20 (dd, 8Hz, 4Hz), 7.02 (s), 6.85 (s br), 6.81 (s br), 6.37 (s br), 6.19 (s br), 5.86 (s), 5.66 (dd, 9Hz, 6Hz), 5.48 (dd, 7Hz, 8Hz), 4.54 (m), 4.01 {m), 3.94 (d, 15Hz), 3.88 (d, 15Hz), 3.55 (dd, 15Hz, 7Hz), 3.37 (dd, 15Hz, 9Hz), 2.85 (ddd, 14Hz, 9Hz, 3Hz), 0.62 d, 7Hz), 0.49 (d, 7Hz
XN Cl R=0.30 (T 4:1). 5 = 8.89 (d, 4Hz), 8.85 (d, 3Hz), 8.01 (d, 8Hz), 7.99 (d, 8Hz), _ F 7.90 (d, 8Hz), 7.86 (d, 8Hz), 7.77 (d,
N 8Hz), 6.87 (dd, 8Hz, 8Hz), 6.45 (s br), 6.23 (s br), 5.97 (s br), 5.61 (dd, 8Hz, 8Hz), 5.46 (dd, 7Hz, 7Hz), 5.39 (s), 4.63 (m), 4.00 (d, 15Hz), 3.89 (d, 14Hz), 2.80 (dd, 13Hz, 11Hz), 0.66 (d, 7Hz), 0.58 (d, THz 11 AN CF, R=0.40 (T 4:1). § = 9.12 (d, 5Hz), 9.08 (d, 4Hz), 8.60 (d, 8Hz), 8.45 (d, 9Hz), ” 8.40 (d, 9Hz), 8.39 (s), 8.39 (s), 8.37
N (d, 10Hz), 8.02 (d, 8Hz), 7.90 (d, 7Hz), 7.87 (s), 7.77 (d, 8Hz), 7.38 (d, 8Hz), 7.18 (d, 8Hz), 6.65 (s br), 6.40 (s br), 6.07 (s), 5.89 (s br), 5.81 (s br), 5.60 (dd, 8Hz, 8Hz), 5.54 (dd, 8Hz, 8Hz), 4.57 (m), 3.98 (d, 16Hz), 3.90 (d, 16Hz), 3.00 (dd, 12Hz, 12Hz), 0.68 (d, 7Hz), 0.58 (d, THz 12 XX F R=0.34 (E two times). 5 = 8.85 (dd, 4Hz, 2Hz), 8.12 (d, 8Hz), 8.07 (d, Hz), : _ F | 7.99 (d, 8Hz), 7.98 (d, 9Hz), 7.90 (d,
N 8Hz), 7.84 (d, 8Hz), 7.77 (d, 8Hz), 7.64 (m), 7.54 (m), 7.42 (dd, 8Hz, 8Hz), } 7.28 (d, 7Hz), 7.21 (dd, 8Hz, 4Hz), 7.10 (dd, SHz, 9Hz), 6.60 (m), 6.51 (d, 9Hz), 6.43 (s br), 6.33 (s br), 6.20 (s br), 5.99 (s), 5.60 (dd, 8Hz, 8Hz), 5.46 (dd, 7Hz, 8Hz), 5.37 (s br), 4.64 (m), 4.00 (d, 15Hz), 3.89 (d, 15Hz), 3.52 m), 3.41 (dd, 15Hz, 8Hz), 2.79 (dd,
(Ex | Rl OR | DATA . | 13Hz, 11Hz), 0.66 (d, 7Hz), 0.60 (d, 7Hz 12a R=0.75 (T 4:1). 6 = 8.85 (d, 3Hz; Ar),
N 8.02 (d, 8Hz; ar), 7.99 (d, 8Hz; ar), _ 7.88 (2d, 8Hz; ar), 7.77 (d, 8Hz; ar),
N 7.66 (s; ar), 7.56 (s; ar), 7.29 (s; 3-H A) . N 16.43 (s br; NH A), 6.25 (s br; NH B), 6.01 (s; 3-H B), 5.72 (s br; NH B), 5.61 (t, 8Hz; B), 5.56 (s br; NH A), 5.47 (t, 8Hz; A), 4.63 (m; B), 4.00 (d, 15Hz), 3.90 (d, 15Hz), 3.43 (dd, 15Hz, 8Hz;
A), 2.83 (dd, 10Hz, 4Hz; A), 0.62 (d, 7Hz; 5-Me A), 0.54 (d, 7Hz; 5-Me B 12b SN R=0.25 (T). NMR in MeOD: § = 9.2- 8,85 (m; ar), 8.97 (s; ar) 8.1-7.1 (m;
PP ar), 7.20 (s; 3-H A), 6.91 (s, 3-H B),
N 4.41 (m; 5B), 3.97 (m; 5 A), 0.63 (d, 7Hz; 5-Me A), 0.45 (d, 7Hz; 5-Me B) “7
NN
12¢ SN R=0.40 (T 4:1). 5 = 8.88 (dd, 4Hz, 1.5Hz; ar B), 8.84 (dd, 4Hz, 1.5Hz; ar _ A), 8.10/8.07 (2d, 9Hz; ar B) 8.00/7.97
N CF (2d, 9Hz; ar A), 7.90/7.83/7.76 (3d, 3 | 8Hz, ar), 7.32 (s; ar), 7.15 (s; ar), 7.01/6.77 (2d, 8Hz), 6.55 (s br; NH A), 6.32 (s br; NH B), 6.03 (s; 3-H B), 5.66 (t, 8Hz; alpha-H B), 5.59 (s br, NH B), 5.50 (t, 7.5Hz; alpha-H A), 5.49 (s br;
NH A), 4.63 (m; 5 B), 3.93 (m; 5 A), 4.00 (d, 15Hz), 3.89 (d, 15Hz), 2.80 (dd, 11Hz, 13Hz), 0.57 (d, 7Hz, 5-Me
A), 0.54 (d, 7Hz; 5-Me B 13 o F R=0.67 (T). & = 8.01 (d, 8Hz), 7.88 (d, 8Hz), 7.77 (d, 8Hz), 7.59 (ddd, 8Hz,
Ag y THz, 1Hz), 7.52 (dd, THz, THz), 7.43 0 (dd, 8Hz, 8Hz), 7.31 (d, 7Hz), 7.27 (s), : 7.04 (d, 8Hz), 6.96 (d, 9Hz), 6.75 (d, 8Hz), 6.73 (d, 1Hz), 6.67 (m), 6.52 (d, 8Hz), 6.43 (d, 8Hz), 6.36 (s br, NH), 5.98 (s), 5.84 (d, 1Hz), 5.75 (d, 1Hz), 5.66 (dd, 8Hz, 8Hz), 5.58 (s br, NH), 5.47 (dd, 7Hz, THz), 4.58 (m), 3.89 (m), 3.73 (d, 15Hz), 3.60 (d, 15Hz), 3.35 (d, 15Hz), 3.30 (d, 13Hz), 2.77 (dd, 13Hz, 11Hz), 0.60 (d, 7Hz), 0.56 d, 7Hz 14 o R=0.55 (T 4:1). 8 = 8.01 (d, 8Hz), 7.88 (d, 8Hz), 7.78 (d, 8Hz), 6.43 (d, 8Hz), > 5.96 (s br), 5.87 (d, 1Hz), 5.84 (d, 0) ci 1Hz), 5.8 (d, 1Hz), 5.75 (d, 1Hz), 5.66 (dd, ~7.5Hz, ~7.5Hz2), 5.45 (dd, ~7.5Hz, ~7.5Hz), 4.58 (ddq, 7Hz,
(EX OR RT Ata] } 13Hz), 3.89 (ddq, 7Hz, 12Hz, 6Hz2), 2.77 (dd, 14Hz, 11Hz), 0.61 (d, 7Hz), 0.55 (d, 7Hz lo) CF, R=0.75 (T). 3 = 7.94 (d, 8Hz), 7.80 (d, 8Hz), 7.70 (d, 8Hz), 7.70 (d, 8Hz), 7.51 “Cr > (ddd, 8Hz, 7Hz, 1Hz), 7.16 (d, 9Hz), . 0) 6.77 (s), 6.72 (s), 6.65 (m), 6.45 (d, 8Hz), 6.36 (d, 8Hz), 6.27 (s br), 5.94 (s br), 5.79 (d, 1Hz), 5.76 (d, 1Hz), 5.74 : (d, 1Hz), 5.68 (d, 1Hz), 5.63 (dd, 8Hz, 8Hz), 5.58 (s br), 5.44 (s br), 5.41 (dd,
THz, THz), 4.50 (m), 3.83 (m), 3.67 (d, 15Hz), 3.563 (d, 15Hz), 3.39 (dd, 15Hz, 7Hz), 3.19 (d, 15Hz), 2.89 (d, 16Hz), 2.72 (dd, 13Hz, 11Hz), 0.46 (d, 7Hz), 0.39 (d, 7Hz 16 o Cl R=0.53 (E). 5 = 8.01 (d, 8Hz), 7.89 (d, “CL S . 8Hz), 7.78 (d, 8Hz), 7.60 (ddd, 8Hz,
THz, 1Hz), 7.53 (ddd, 8Hz, 7Hz, 1Hz), (0) 7.43 (dd, 8Hz, 7Hz), 7.43 (dd, 8Hz, 7Hz), 7.36 (d, 7Hz), 7.31 (d, 8Hz), 7.21 (s), 7.07 (d, 9Hz), 6.97 (dd, 8Hz, 9Hz), 6.53 (dd, 8Hz, 1Hz), 6.45 (s br), 6.45 (d, 8Hz), 6.25 (s br), 5.92 (s), 5.88 (d, 1Hz), 5.85 (d, 1Hz), 5.82 (d, 1Hz), 5.76 : (d, 1Hz), 5.65 (dd, 8Hz, 8Hz), 5.43 (dd, 7Hz, THz), 5.36 (s br), 4.59 (m), 3.92 (m), 3.74 (d, 15Hz), 3.61 (d, 15Hz), 3.31 (d, 15Hz), 2.78 (dd, 13Hz, 11Hz), 0.64 (d, 7Hz), 0.57 (d, 7Hz 16a 0 R=0.31 (T 4:1). § = 8.01 (d, 8Hz ar), 7.89 (d, 8Hgz; ar), 7.79 (d, 8Hz; ar), 7.43 (ddd, 8Hz, 5Hz, 5Hz), 7.25 (s; H-3 0 N A), 6.75 (d, 8Hz), 6.73 (d, 1Hz), 6.66 (d, 8Hz), 6.52 (d, 8Hz), 6.46 (d, 8Hz), 6.41 (s; br NH A), 6.26 (s; br NH B), 5.97 (s; H-3 B), 5.85/5.77 (2s; OCH,0
A), 5.66 (t, 8Hz), 5.59 (s; br NH B), 5.47 (s; br NH A), 5.45 (t, 8Hz), 4.59 (m; 5B), 3.95 (m; 5 A), 3.74 (qd, 15Hz), 3.62 (d, 15Hz), 3.29 (d, 15Hz), 2.81 (ddd, 8Hz, 7Hz, 4Hz; 7), 0.60 (d, THz 5-Me A), 0.49 (d, 7Hz; 5-Me B 16b 0 R~=0.68 (CH,Cl,/i-PrOH 20:1). 8 = 8.02 (d, 8Hz, ar), 7.88 (d, 8Hz; ar), 7.78 (d, 8Hz; ar), 7.59 (m; ar), 7.52 (m; ar), 0 CF 7.43 (m; ar), 7.12 (s; 3-H A), 6.73 (m), 3 16.52 (d, 8Hz), 6.44 (d, 8Hz), 6.45 (s; br
NH A), 6.35 (s; br NH B), 5.98 (s; H-3 : B), 5.84/5.76 (2s; OCH,0 A), 5.86/5.80 (2s; OCH,0 B), 5.69 (t, 8Hz), 5.57 (s; br NH B), 5.48 (t, 8Hz), 5.46 (s; br NH
A), 4.58 (m; 5B), 3.89 (m; 5 A), 3.73 (d, 15Hz), 3.60 (d, 15Hz), 3.29 (d, 15Hz), 2.79 (m), 0.56 (d, 7Hz; 5-Me A),
IE ET
G51 [@, Hz Me) 17 Cl R=0.47 (E). 5 = 8.00 (d, 8Hz), 7.89 (d, 8Hz), 7.89 (d, 7Hz), 7.79 (d, 8Hz), 7.61 . (ddd, 8Hz, 7Hz, 1Hz), 7.54 (ddd, 8Hz,
THz, 1Hz), 7.45 (dd, 8Hz, 7Hz), 7.05 (d, 7Hz), 6.66 (s), 6.64 (s), 6.59 (s br), . 6.33 (s br), 5.96 (s), 5.62 (dd, 8Hz, 8Hz), 5.55 (s br), 5.48 (s br), 5.45 (dd, 7Hz, THz), 4.59 (m), 3.86 (d, 15Hz), 3.70 (d, 14Hz), 3.58 (dd, 16Hz, 8Hz), 3.42 (dd, 15Hz, 8Hz), 2.62 (dd, 13Hz, 11Hz), 1.80 (ddd, 15Hz, 6Hz, 6Hz), 0.59 (d, 7Hz), 0.54 (d, THz 18 F R=0.75 (T). 5 = 8.04 (d, 8Hz), 7.89 (d, 8Hz), 7.77 (d, 8Hz), 7.59 (ddd, 8Hz,
THz, 1Hz), 7.52 (dd, 8Hz, 7Hz), 7.27
CF (s), 6.68 (d, 8Hz), 6.60 (s br), 6.56 (d, 3 8Hz), 6.33 (s br), 5.90 (s), 5.68 (dd, 8Hz, 8Hz), 5.60 (s br), 5.54 (dd, THz,
THz), 5.50 (s br), 4.57 (m), 3.80 (m), 3.80 (d, 15Hz), 3.70 (d, 15Hz), 3.30 (dd, 13Hz, 11Hz), 2.83 (dd, 13Hz, 11Hz), 0.59 (d, 7Hz), 0.58 (d, 7Hz 19 Cl R=0.47 (T 4:1). 8 = 8.07 (d, 8.5Hz), 8.01 (d, 8.5Hz), 7.86 (d, 8Hz), 7.78 (d,
Ci 8Hz), 7.74 (d, 8Hz), 7.55 (d, 8Hz), 6.68 (s, br), 6.34 (s, br), 6.28 (s), 5.63 (dd, 5.5Hz, 9Hz), 5.55 (dd, 8Hz, 8Hz), 5.48
Ci (s, br), 4.64 (m), 4.41 (d, 16.5Hz), 4.14 (d, 16.5Hz), 4.02 (d, 16.5Hz), 3.97 (m), : 3.68 (dd, 8.5Hz, 8.5Hz), 3.32 (dd, 11Hz, 14Hz), 0.79 (d, 7Hz), 0.70 (d,
THz)
F Ri=0.55 (E two times). 5 = 8.05 (d, 8Hz), 7.93 (d, 8Hz), 7.79 (d, 8Hz), 7.63
F (ddd, 8Hz, 7Hz, 1Hz), 7.44 (dd, 8Hz, 8Hz), 7.20 (s), 7.18 (d, 8Hz), 7.06 (d,
CN 8Hz), 6.52 (s br), 5.79 (s), 5.63 (dd, 9Hz, 6Hz), 5.45 (s br), 4.56 (m), 3.78 (d, 15Hz), 3.66 (d, 15Hz), 2.70 (dd, 14Hz, 11Hz), 0.64 (d, 7Hz), 0.60 (d,
THz 21 R=0.55 (T 4:1). 5 = 7.98 (d, 8H4z), 7.95 “TL (d, 8Hz), 7.84 (d, 7THz), 7.81 (d, 9Hz), 7.71 (d, 8Hz), 7.35 (dd, 8Hz, 8Hz),
CN 7.24 (d, 8Hz), 7.16 (s), 7.08 (d, 8Hz),
Cl | 6.98 (d, 8Hz), 6.69 (d br, 8Hz), 6.66 (s), 6.59 (s br), 6.28 (s br), 5.73 (s), 5.61 (dd, 8Hz, 7Hz), 5.58 (dd, 9Hz, 6Hz), 5.52 (s br), 4.45 (m), 3.70 (d, 15Hz), 3.62 (m), 3.58 (d, 15Hz), 3.41 (d, 15Hz), 3.22 (dd, 12Hz, 12Hz), 2.64 (dd, 13Hz, 11Hz), 1.98 (s), 1.79 (s), 0.53 (d, 7Hz), 0.49 (d, THz
EX | RR ~~ [RT ~~ pAA_ 22 Ri=0.40 (T 4:1). 5 = 7.96 (d, 9Hz), 7.95 (d, 8Hz), 7.84 (d, 8Hz), 7.80 (d, 8Hz), 7.72 (d, 8Hz), 7.48 (d, 7Hz), 7.40 (dd,
NH 8Hz, 8Hz), 7.22 (d, THz), 6.98 (d, 8Hz), 2 Cl | 6.73 (d, 8Hz), 6.11 (d, 8Hz), 5.92 (s), 5.52 (dd, 7Hz, 6Hz), 5.42 (s br), 4.50 . (m), 3.79 (m), 3.65 (d, 15Hz), 3.49 (d, 14Hz), 3.41 (dd, 8Hz, 16Hz), 2.52 (dd, 12Hz, 12Hz), 0.51 (d, 7Hz), 0.45 (d, 7Hz 23 CF, R=0.57 (T). & = 7.99 (d, 8Hz), 7.97 (d, 8Hz), 7.84 (d, 8Hz), 7.73 (d, 8Hz), 7.54 “CL (ddd, 8Hz, THz, 1Hz), 7.45 (s), 6.97 (d,
NH 8Hz), 6.75 (d, 8Hz), 6.59 (d, 8Hz), 6.17 2 (d, 8Hz), 5.96 (s), 5.76 (s br), 5.61 (dd, 8Hz, 7Hz), 5.46 (dd, 7Hz, 7Hz), 4.50 (m), 3.83 (m), 3.67 (d, 15Hz), 3.51 (d, 15Hz), 2.56 (dd, 13Hz, 10Hz), 0.45 (d, 7Hz), 0.39 (d, 7Hz 24 CF, R=0.53 (T 4:1). § = 7.97 (d, 8Hz), 7.84 (d, 7Hz), 7.74 (d, 8Hz), 7.31 (s), 7.24
CH (d, 7THz), 7.06 (d, 9Hz), 6.80 (d, 8Hz), pd 3
N 6.73 (s), 6.59 (d, 9Hz), 6.53 (s br), 6.16 (d, 9Hz), 6.05 (s), 5.61 (dd, 8Hz, 8Hz),
CH, 5.46 (dd, 7Hz, THz), 5.33 (s br), 5.27 (s br), 4.55 (m), 3.85 (m), 3.73 (d, 15Hz), 3.53 (d, 15Hz), 3.22 (d, 15Hz), 2.73 (s), 2.58 (s), 0.45 (d, 7Hz), 0.38 (d, 7Hz
NH, Cl R=0.65 (T, free base). § =7.98 (d, 8Hz), 7.85 (d, 7Hz), 7.77 (d, 8Hz), 7.75 (d, 8Hz), 7.18 (m), 6.58 (s br), 6.31 (s br), 6.00 (s), 5.35 (m), 4.93 (m), 4.45 (m), 3.44 (d, 15Hz), 3.22 (dd, 13Hz, 11Hz), 0.58 (d, 7Hz), 0.50 (d, 7THz) 26 CF, R=0.31 (T) tailing. 5 = 9.00 (s), 8.79 (s), 7.97 (d, 9Hz), 7.83 (d, 8Hz), 7.72 (d, 8Hz), 7.15 (s), 7.10 (d, 8Hz), 7.02 (d, 8Hz), 6.86 (s), 6.65 (s br), 6.16 (s br), 6.00 (s br), 5.89 (s), 5.64 (dd, 8Hz,
COOH 8Hz), 5.41 (dd, 7Hz, THz), 4.50 (m), 3.86 (m), 3.72 (d, 15Hz2), 3.62 (d, ") 15Hz), 3.26 (d, 15Hz), 2.70 (dd, 13Hz, 11Hz), 2.53 (m), 1.82 (m), 0.46 (d, 7Hz), 0.39 (d, 7Hz) lo}
EXT ~ "RR TR, oAatA_____ 1] : 27 R=0.30 (T). 6 = 8.15 (d, 9Hz), 8.09 (d, 8Hz), 7.91 (d, 8Hz), 7.91 (d, 8Hz), 7.80 (d, 8Hz), 7.52 (m), 7.40 (dd, 8Hz, 7Hz), . 7.36 (d, 8Hz), 7.13 (d, 8Hz), 6.95 (s),
Cl | 6.85 (d, 8Hz), 6.65 (s), 5.82 (s), 5.79
COOH (dd, 10Hz, 6Hz), 5.59 (dd, 10Hz, 6Hz), : 4.47 (m), 4.05 (m), 3.76 (m), 3.48 (dd,
HN 14Hz, 10Hz), 2.92 (dd, 14Hz, 11Hz), 2.62 (m), 2.51 (m), 0.54 (d, 7Hz), 0.46 (d, 7Hz) lo] 28 Cl R=0.65 (T). 5 = 8.42 (s), 8.37 (s), 7.98 (d, 8Hz), 7.84 (d, 8Hz), 7.74 (d, 8Hz), 7.55 (dd, 7Hz, 7Hz), 7.40 (d, 8Hz), 7.35 (d, THz), 7.13 (s), 6.82 (s), 6.80 (s), 6.67 (s br), 6.29 (s br), 5.96 (s),
COOH 5.37 (s br), 4.99 (s br), 4.48 (m), 3.78 (d, 15Hz), 3.22 (dd, 12Hz, 13Hz), 0.57 i") (d, 7Hz), 0.49 (d, 7Hz) lo] 29 R=0.45 (RP-8, MeOH/H,O/TFA 70:30:1). 5 = 8.18 (d, 9Hz), 8.09 (d, 8Hz), 7.91 (d, 8Hz), 7.90 (d, 8Hz), 7.79 (d, 8Hz), 7.49 (d, 8Hz), 7.38 (dd, 8Hz,
Cl | 8Hz), 6.93 (s), 6.88 (s), 6.87 (d, 8Hz), 6.59 (s), 5.81 (dd, 10Hz, 6Hz), 5.78 (s),
NH, 5.56 (dd, 10Hz, 6Hz), 4.44 (m), 4.07
HN (m), 3.81 (s), 3.77 (s), 3.72 (s), 3.23 (dd, 13Hz, 11Hz), 3.01 (dd, 14Hz, 10Hz), 0.52 (d, 7Hz), 0.44 (d, THz) lo]
Ci 5=19.84 (s br), 9.79 (s br), 7.98 (d, 8Hz), 7.84 (d, 8Hz), 7.74 (d, 8Hz), 7.53
NH (dd, THz, 7Hz), 7.47 (dd, THz, 8Hz), 2 7.40 (d, THz), 7.25 (s), 6.95 (dd, THz, 8Hz), 6.80 (d, 8Hz), 6.74 (s br), 6.24 (s br), 5.95 (s), 5.44 (s br), 4.96 (s br), 0 4.44 (m), 3.19 (dd, 13Hz, 12Hz), 2.73
N (dd, 11Hz, 11Hz), 0.54 (d, 7Hz), 0.48
H (d, 7H2)
31 R=0.52 (BUOH/MeOH/H,O/AcOH 10:5:2:1). = 8.16 (d, 8Hz), 8.09 (d, 9Hz), 7.91 (d, 8Hz), 7.80 (d, 8Hz), 7.60 ) (d, 9Hz), 7.57 (ddd, 8Hz, 7Hz, 1Hz),
Cl | 7.46 (m), 7.40 (dd, 8Hz, THz), 7.29 (s), 7.18 (d, 8Hz), 6.94 (s), 6.89 (d, 8Hz), . 6.63 (s), 5.81 (s), 5.79 (dd, 10Hz, 6Hz), 5.57 (dd, 10Hz, 6Hz), 4.46 (m), 4.08
HN NH, (m), 3.78 (s), 3.70 (dd, 15Hz, 6Hz), hia 3.58 (m), 3.48 (dd, 15Hz, 10Hz), 3.23 (dd, 6Hz, 6Hz), 3.11 (dd, 13Hz, 7Hz), 0] 2.99 (dd, 13Hz, 11Hz), 2.75 (dd, 6Hz, 6Hz), 2.62 (dd, 13Hz, 7Hz), 0.53 (d, 7Hz), 0.45 (d, THz 32 R=0.65 (T). 5 = 8.04 (m br), 7.94 (d, . | THz), 7.81 (d, 8Hz), 6.73 (s), 6.62 (s br), 6.36 (d, 16Hz), 6.30 (d, 17Hz), 5.96 (s), 5.73 (d, 8Hz), 5.65 (d, 9Hz),
Cl | 555 (m Br), 4.57 (m), 0.59 {(d), 0.55 (d, 6Hz) : CH, nn 0 33 Rr=0.42 (T). 5 = 8.04 (d, 8Hz), 8.00 (d, 9Hz), 7.93 (d. 8Hz), 7.88 (d, 8Hz), 7.80 (d, 8Hz), 7.76 (s), 7.07 (d, 8Hz), 6.98 : o (d, 8Hz), 6.94 (s), 6.66 (s), 6.62 (s br),
Cl | 5.96 (s), 5.59 (dd, 8Hz, 8Hz), 5.51 (dd,
NY THz, THz), 4.58 (m), 3.83 (m), 3.76 (d, i" Ls 15Hz), 3.64 (m), 3.58 (m), 3.47 (m), 2.62 (m), 0.58 (d, 7Hz), 0.54 (d, 7Hz) (0) 34 Ri=0.37 (RP-8 MeOH/H, OFA 70:30:12). 5 = 9.90 (s br), 8.22 (d, 8Hz), 8.18 (d, 8Hz), 7.95 (d, 8Hz), 7.82 0 (d, 8Hz), 7.51 (d, 8Hz), 7.34 (m), 7.25
Cl 1 (s), 7.11 (d, 8Hz), 7.02 (d, 9Hz), 6.69
NT (s). 5.60 (dd, 10Hz, 5Hz), 5.45 (dd, a L_w 10Hz, 5Hz), 4.35 (m), 4.14 (dd, 5Hz, 5Hz), 4.06 (m), 3.76 (d, 16Hz), 3.70 (d, i 15Hz), 0.48 (d, 6Hz), 0.39 (d, 7Hz)
Ci R=0.42 (E). 5 = 8.04 (d, 9Hz), 7.89 (d, : 8Hz), 7.77 (d, 8Hz), 7.59 (ddd, 8Hz, “10 7Hz, 1Hz), 7.52 (ddd, 8Hz, 7Hz, 1Hz),
CH.O 7.42 (dd, 8Hz, 7Hz), 6.84 (d, 8Hz), : 3 6.66 (dd, 7Hz, 7Hz), 6.60 (s br), 6.34 (s br), 6.13 (s), 5.59 (dd, 8Hz, 8Hz), 5.44 (dd, 7Hz, 7Hz), 5.37 (s br), 4.58 (m), 3.88 (m), 3.80 (s), 3.74 (s), 3.72 (d, 6Hz), 3.42 (ad, 15Hz, 8Hz), 3.31 (ddd, 13Hz, 10Hz, 2Hz), 2.92 (dd, 13Hz,
. 1 11H2),0.63 (d, 7H2), 0.53 (4. THz 36 Cl R=0.44 (E). 5 = 7.97 (d, 9Hz), 7.83 (d, 9Hz), 7.73 (d, 8Hz), 7.52 (dd, 8Hz, . 8Hz), 7.35 (dd, 7Hz, THz), 6.83 (d,
OCH 9Hz), 6.62 (d, 8Hz), 6.58 (s br), 6.49 3 (s), 6.32 (d, 9Hz), 5.89 (s), 5.57 (dd, : 8Hz, 7Hz), 5.47 (dd, THz, 7Hz), 5.41 (s br), 4.51 (m), 3.71 (s), 3.60 (s), 3.56 (d, 9Hz), 3.38 (s), 2.53 (dd, 13Hz, 11Hz), 1.71 (ddd, 15Hz, 6Hz, 6Hz), 0.51 (d,
THz), 0.46 (d, 7Hz 37 Cl Cl Ri=0.37 (E). 5 = 8.06 (d, 8Hz), 8.01 (d, 8Hz), 7.90 (d, 8Hz), 7.81 (d, 8Hz), 7.59 (dd, 7Hz, 7Hz), 7.52 (dd, 8Hz, 8Hz),
OCH 7.48 (dd, 8Hz, 8Hz), 7.16 (s), 6.86 (dd, 3 8Hz, 7Hz), 6.80 (d, 8Hz), 6.71 (s), 6.69 (dd, 8Hz, 2Hz), 6.65 (s br), 6.36 (s br), 6.07 (d, 8Hz), 5.91 (s), 5.66 (dd, 8Hz, 8Hz), 5.60 (dd, 7Hz, 7Hz), 5.51 (s br), 4.57 (m), 3.76 (s), 3.73 (d, 15Hz), 3.52 (s), 2.69 (dd, 13Hz, 11Hz), 0.60 (d, 7Hz), 0.57 (d, THz 38 Ci Rr=0.46 (toluene/i-PrOH 4:1). §=8.07 | ~ -CH;, (d, 8Hz), 8.00 (d, 8Hz), 7.87 (dd, 8Hz, 2Hz), 7.76 (d, 8Hz), 7.57 (ddd, 8Hz, 7Hz, 1.5Hz), 7.50 (ddd, 8Hz, 7Hz, 1Hz), 7.43 (dd, 7Hz, 7Hz), 7.23 (m), 6.68 (s br,), 6.42 (s br), 5.79 (s), 5.70 (dd, 10Hz, 6Hz), 5.61 (s, br), 5.52 (dd, 8Hz, 8Hz), 4.55 (m), 3.68 (m), 3.34 (dd), 3.10 (dd, 13.5Hz, 11Hz), 2.09 (s), 0.64 (d, 7Hz), 0.59 (d, 7Hz
PREPARATION OF STARTING MATERIALS
Naphythylalanine amide (Compound A1)
Naphthalene-1-carboxylic acid is dissolved in dry THF and 5 equiv. of borane dimethylsulfide complex are added. The mixture obtained is stirred at rt, diluted with EtAc, washed with 1N
HCI and 5% NaHCO; solution, dried and solvent is evaporated. (Naphthalene-1-yl)-methanol is obtained, which is dissolved in CH,Cl,. To the solution obtained 1.5 equiv. of Dess-Martin reagent are added at rt. The mixture obtained is diluted with EtAc, extracted with 1N HCI . and 5% NaHCOs-solution, dried and solvent is evaporated. Naphthalene-1 -carboxaldehyde is obtained and dissolved with 1 equiv. of racemic-Boc-a-phosphonoglycine trimethylester in } CH,Cl; and 1.1 equiv. of DBU are added. The mixture obtained is stirred at rt and treated in sequence with 1N HCI and 5% NaHCO; solution. The phases obtained are separated, the organic phase obtained is dried and solvent is evaporated. 2-Boc-amino-3-(naphthalene-1- yl)-acrylic acid methyl ester (cis/trans mixture) is obtained, is dissolved in MeOH/H,0 at pH
6.5 (phosphate buffer) and 20 w/w% of 10% Pd/C are added. The mixture obtained is : hydrogenated at rt and 50 bar, the catalyst is filtered off and from the filtrate obtained solvent is evaporated. Racemic naphythylalanine methylester is obtained, dissolved in methanolic
NH; and stirred. The mixture obtained is subjected to extractive work up. Racemic naphythylalanine amide is obtained.
TEST Example
Inhibition of allergic contact dermatitis (ACD) in vivo a. Method:
Groups of 8 female mice are sensitized epicutaneously with 50 pl of 2% oxazolone on the shaved ventral abdomen (day 1) and challenged with 10 pl of 0.2% oxazolone on the inner surface of the right ear (day 8). The unchallenged left ears serve as normal controls and dermatitis is evaluated from the difference in pinnal weight which is taken as a measure of inflammatory swelling (day 9). In addition, activity of myeloperoxidase (MPO) serving as a measure of leukocyte influx in ear homogenates are determined as described by Bradiey et - al., J.Invest.Dermatol; 78:206-209 (1982). The animals are treated orally 2 hours after challenge with the test compound of example 10. Activity is calculated as the percentage of inhibition of inflammatory auricular swelling and of MPO activity relative to animals treated with the vehicle alone. For comparison mice are treated intraperitoneally with 100 pl monoclonal anti-mouse LFA-1 antibody 1 hour before challenge and evaluated as described. b) Results
Oral treatment with a single dose of 0.01-10.0 mg/kg of a compound of example 10 results in an inhibition of the inflammatory response by 40-50%. Inhibition of swelling compared with inhibition of MPO activity is observed. Treatment with 50-200 pg/mouse anti-LFA-1 antibody results in an inhibition by 34-56%.
Claims (20)
1. A compound of formula . 0 Oo R, S—N N—4 l Dal oo wherein Ry is (Cy4)alkyl, Rz is unsubstituted (Cs4)alkyl or (Ci4)alkyl substituted by unsubstituted or substituted - (Ceg)aryl or - (Ce.16)aryl annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S, Rs is (Ce.1s)aryl one or morefold substituted by - halogen, - halo(C,.5)alkyl, - halo(C,.¢)alkoxy, - cyano, - phenyl, - heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O,
S.
2. A compound of claim 1 wherein R; is methyl, R2 is methyl or methyl substituted by ’ - quinolinyl, - benzof1,3]dioxolyl, ’ - phenyl - phenyl one or morefold substituted by halogen, halo(C,4)alkyl, (Cy4)alkoxy, cyano, amino, dimethylamino, carboxy(Cs.z)alkylcarbonylamino, amino(C,.;)alkylcarbonylamino, (Cz4)alkylenecarbonylamino,
heterocyclylcarbonyl(C,.,)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O, - Rj is phenyl one or morefold, e.g. 1- to 3-fold, substituted by - halogen, - halo(C.o)alkyl, - halo(C,.;)alkoxy, - cyano, - phenyl, - heterocyclyl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms.
3. A compound selected from the group consisting of 2-[3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, 2-[5-Methyl-2-ox0-4-(quinolin-6-yl-acetyl)-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-(4-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-(2-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-(3-Bromo-phenyl)-5-methyl-2-ox0-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-Biphenyl-3-yl-5-methyl-2-0x0-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen- 1-yl-propionamide, 2-[3-(3-Chloro-phenyl)-5-methyl-2-ox0-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-(3,5-Dichloro-phenyl)-5-methyl-2-0x0-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-(4-Chloro-3-trifluoromethyl-phenyl)-5-methyl-2-ox0-4-(2-quinolin-6-yl-acetyl )- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, 2-[3-(3-Chloro-4-fluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acety)-[1,4]diazepan-1-yl]- 3-naphthalen-1-yl-propionamide, 2-[5-Methyl-2-ox0-4-(2-quinolin-6-yl-acetyl)-3-(2-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-(3,4-Difluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, AMENDED SHEET
-37A - 2-[3-(3-Cyano-phenyl)-5-methyl-2-ox0-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[5-Methyl-2-0x0-3-(3-pyrimidin-5-yl-phenyl)-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[5-Methyl-2-0x0-4-(2-quinolin-6-yl-acetyl)-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1-yl]- 3-naphthalen-1-yl-propionamide, 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-fluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]- 3-naphthalen-1-yl-propionamide, 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan- 1-yl}-3-naphthalen-1-yl-propionamide 2-[4-(2-Benzo[1,3)dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethyi-phenyl)- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-4-fluoro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-cyano-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}- 3-naphthalen-1-yl-propionamide, 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethoxy-phenyl)- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, 2-[3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-phenylacetyl-[1,4}diazepan-1-yl}-3-naphthalen-1-yl- propionamide, 2-[3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-[(3-trifluoromethyl-phenyl )-acetyl]-[1,4]diazepan-1- yl]-3-naphthalen-1-yl-propionamide, 2-{3-Biphenyl-4-yl-5-methyl-2-oxo-4-[2-(2,3,6-trichloro-phenyl)-acetyl}-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, 2-[4-[2-(4-Cyano-phenyl)-acetyl]-3-(3,4-difluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[3-(3-Chloro-phenyl)-4-[2-(4-cyano-phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, 2-[4-[2-(4-Amino-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3- naphthalen-1-yl-propionamide, 2-[4-[2-(4-Amino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1- yl}-3-naphthalen-1-yl-propionamide, 2-[4-[2-(4-Dimethylamino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, 2-[4-[2-(3-Amino-phenyl)-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-
AMENDED SHEET
- 37B - naphthalen-1-yl-propionamide, N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-7-methyl-3-oxo-2-(3-trifluoromethyl- phenyl)-[1,4]diazepan-1-yl}-2-oxo-ethyl}-phenyl)-succinamic acid, N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyi)-7-methyl-3-oxo-
[1.4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, N-(3-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid, 2-[4-{2-[4-(2-Amino-acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, 2-[4-{2-[3-(2-Amino-acetylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl )-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, 2-[4-{2-[4-(3-Amino-propionylamino)-phenyl]-acetyl}-3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-acrylamide, N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-
[1.4]diazepan-1-yl]-2-oxo-ethyl}-phenyi)-4-morpholin-4-yl-4-oxo-butyramide, N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo- [1,4]diazepan-1-yl}-2-oxo-ethyl}-phenyl)-4-oxo-4-piperazin-1-yl-butyramide, 2-{3-(3-Chloro-phenyl)-4-[2-(2-methoxy-phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3- naphthalen-1-yl-propionamide, 2-{3-(3-Chloro-phenyt)-4-[2-(4-methoxy-phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yi}-3- naphthalen-1-yl-propionamide, 2-[4-[2-(3-Chloro-4-methoxy-phenyl)-acetyl]-(3-(3-chloro-phenyl)-5-methyl-2-oxo- [1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, and 2-[4-Acetyl-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepam-1-yl]-3-naphthalen-1-yi propionamide.
4. A compound according to any one of claims 1 to 4 of formula AMENDED SHEET
- 37C - Cl 0 O HN 4 0 (0) N N 7 (A ‘ ! (O B )
5. A compound of any one of claims 1 to 4 in the form of a salt.
6. A compound of formula | according to any one of claim 1 to 5 for use as a pharmaceutical.
7. A compound for use according to claim 6, wherein the compound of any one of claims 1 to is used for the treatment or prophylaxis of inflammatory conditions, allergic diseases or autoimmune diseases.
8. A compound for use according to any one claims 6 or 7, wherein the compound of any one of claims 1 to 5 is used for the treatment or prophylaxis of psoriasis, rheumatoid arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, (systemic) lupus erythematosus, atopic dermatitis, Sjoergen syndrom, rejection after transplantation or graft vs. host disease. AMENDED SHEET
9. A compound for use according to any one claims 6 to 8, wherein the compound of any one of claims 1 to 5 is used for the treatment or prophylaxis of psoriasis, atopic dermatitis or rheumatoid arthritis.
10. A compound for use according to any one of claims 6 to 9, wherein the compound of any one of claims 1 to 5 is used in combination with another pharmaceutical active agent, either simultanously or in sequence.
11. The use of a compound of any one of claims 1 to 5 for the manufacture of a medicament for the treatment or prophylaxis of disorders or diseases mediated by LFA-1/ICAM-1, LFA- 1/ICAM-2, LFA-1 /ICAM-3 or LFA-1 /JAM-1 interactions.
12. The use according to claim 11, wherein the compound of any one of claims 1 to 5 is used for the manufacture of a medicament for the treatment or prophylaxis of inflammatory conditions, allergic diseases or autoimmune diseases.
13. The use according to any one of claims 11 or 12, wherein the compound of any one of claims 1 to 5 is used for the manufacture of a medicament for the treatment or prophylaxis of psoriasis, rheumatoid arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, (systemic) lupus erythematosus, atopic dermatitis, Sjoergen syndrom, rejection after transplantation or graft vs. host disease.
14. The use according to any one of claims 11 to 13, wherein the compound of any one of claims 1 to 5 is used for the treatment or prophylaxis of psoriasis, atopic dermatitis or rheumatoid arthritis.
15. The use according to any one of claims 11 to 14, wherein the compound of any one of claims 1 to 5 is used in combination with another pharmaceutical active agent, either simultaneously or in sequence.
16. A pharmaceutical composition comprising a compound of formula | according to any one of claim 1 to 5 in association with at least one pharmaceutical excipient. AMENDED SHEET
- 38A -
17. A pharmaceutical composition according to claim 16, further comprising another pharmaceutically active agent.
18. A compound of any one of claims 1 to 4, substantially as herein described and exemplified.
19. The use according to claim 11, substantially as herein described and exemplified.
20. A pharmaceutical composition according to claim 16, substantially as herein described and exemplified. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0301561A GB0301561D0 (en) | 2003-01-23 | 2003-01-23 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200504672B true ZA200504672B (en) | 2006-05-31 |
Family
ID=9951671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200504672A ZA200504672B (en) | 2003-01-23 | 2005-06-08 | Diazepanes derivatives useful as LFA inhibitors |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN100378096C (en) |
GB (1) | GB0301561D0 (en) |
ZA (1) | ZA200504672B (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ECSP003707A (en) * | 1999-10-13 | 2002-05-23 | Novartis Ag | DIAZEPANES |
AR030817A1 (en) * | 2000-10-02 | 2003-09-03 | Novartis Ag | DERIVATIVES OF DIAZACICLOALCANODIONA |
-
2003
- 2003-01-23 GB GB0301561A patent/GB0301561D0/en not_active Ceased
-
2004
- 2004-01-22 CN CNB2004800021638A patent/CN100378096C/en not_active Expired - Fee Related
-
2005
- 2005-06-08 ZA ZA200504672A patent/ZA200504672B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1735609A (en) | 2006-02-15 |
CN100378096C (en) | 2008-04-02 |
GB0301561D0 (en) | 2003-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2927231B1 (en) | Imidazopyridine compounds | |
EP1184376B1 (en) | Novel heterocyclic carboxamide derivatives | |
JP4135318B2 (en) | Novel pyrimidine-5-carboxamide derivatives | |
WO2018196677A1 (en) | Fluoroallylamine derivative and use thereof | |
KR102156398B1 (en) | Alk kinase inhibitors | |
ES2243441T3 (en) | FOUNDED IMIDAZOLIO DERIVATIVES. | |
KR20120085738A (en) | Pyrrolo [1,2-b] pyridazine derivatives as janus kinase inhibitors | |
CA2672101A1 (en) | Compounds and compositions as kinase inhibitors | |
CA3165889A1 (en) | Pyridazinyl-thiazolecarboxamide compound | |
US6753340B2 (en) | (4,2-disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors | |
JP2007533635A (en) | Vanilloid receptor ligands and their use in therapy | |
EP3022186B1 (en) | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | |
JP4167806B2 (en) | Mevinolin derivatives | |
JP2021531310A (en) | Boronic acid derivative | |
JP3889623B2 (en) | Substituted diazepanes | |
CA3037971A1 (en) | New benzimidazoles derivatives as tec kinases family inhibitors | |
JP4622047B2 (en) | Novel heterocyclic carboxamide derivatives | |
CA3203285A1 (en) | Heteroaryl carboxamide compound | |
AU2017274110B2 (en) | Crystalline form of compound suppressing protein kinase activity, and application thereof | |
AU2004205504B2 (en) | Diazepanes derivatives useful as LFA inhibitors | |
EP2142518B1 (en) | 3,4-dihydroquinazoline derivatives | |
ZA200504672B (en) | Diazepanes derivatives useful as LFA inhibitors | |
CA2854159A1 (en) | N- (3-{[(3-{[2-chloro-5-(methoxy)phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3- kinase inhibitor for the treatment of lymphoproliferative malignancies | |
WO1998054185A1 (en) | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones | |
CA3141747A1 (en) | New tricyclic 5-ht2 antagonists |